question: What is the associated phenotype for the SLCO1B1 *1/*5 diplotype?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *1/*5 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*8 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*6 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*27 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*26 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*5 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*20 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*42 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*7 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*37 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My patient has a SLCO1B1 *1/*10 diplotype. What is the phenotype for this diplotype?
retrieved_docs: [Document(page_content='\ufeffPatients with the SLCO1B1 Diplotype *1/*1 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*10 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *10/*10 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*20 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *10/*27 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*30 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*7 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*9 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*24 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*27 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My patient's PGx result indicates CYP2C9 *2 *6 diplotype. Does this mean she is a poor metabolizer?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *6/*26  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*6  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*23  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*28  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*8  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*46  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*12  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*42  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*42  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: What is the  phenotype for  SLCO1B1 *6/*31 diplotype?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *6/*6 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*32 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*36 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*27 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*30 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*33 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*37 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*8 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*28 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*34 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My patient has the ABCG2 rs2231142 reference on both alleles, is this mean she has normal function?
retrieved_docs: [Document(page_content="Patients with ABCG2 Diplotype 'rs2231142 reference (G)/rs2231142 variant (T)' display ABCG2 Decreased Function Phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n", metadata={'link': '', 'source': 'ABCG2 Diplotype Phenotype Mapping'}), Document(page_content="Patients with ABCG2 Diplotype 'rs2231142 variant (T)/rs2231142 variant (T)' display ABCG2 Poor Function Phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.", metadata={'link': '', 'source': 'ABCG2 Diplotype Phenotype Mapping'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='one decreased function allele (rs2231142; c.421C>A) has ABCG2 \ndecreased function, and an individual with two decreased \nfunction alleles has ABCG2 poor function. rs2231142 can be \ngenotyped alone (e.g., polymerase chain reaction–  based single \nSNP assay) or multiplexed on a variety of array-  based platforms. \nVarious commercial genotyping platforms include rs2231142 in \npanels of pharmacogenetic variants.12Table 1 Assignment of predicted SLCO1B1, ABCG2, and CYP2C9 likely phenotype based on genotype\nGene Phenotypea,bActivity score \n(if applicable) Genotype Examples of diplotypes\nSLCO1B1 Increased function n/a An individual carrying two increased \nfunction alleles*14/*14\nNormal function n/a An individual carrying two normal \nfunction alleles or one normal plus one \nincreased function allele*1/*1, *1/*14\nDecreased function n/a An individual carrying one normal or \nincreased function allele plus one no \nfunction allele*1/*5, *1/*15,', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 normal function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What are some diplotypes for SLCO1B1 Increased Function impacting statins?
retrieved_docs: [Document(page_content='16 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  TABLE S1.  EVIDENCE LINKING SLCO1B1 GENOTYPE WITH STATIN PHENOTYPE  Type of experimental model (in vitro, in vivo preclinical, or clinical) Major Findings References Level of Evidence Atorvastatin In vitro SLCO1B1 is the major atorvastatin uptake transporter.  The average contribution to atorvastatin uptake was SLCO1B1 > SLCO1B3 >> OATP2B1 > NTCP. Vildhede, et al. (2014) (83) Weak In vitro  SLCO1B1 rs4149056 (c.521T>C, *5) reduces atorvastatin transport activity by decreasing OATP1B1 function due to sorting errors in transporter localization Kameyama, et al. (2005) (84) Weak Clinical SLCO1B1 rs4149056 (c.521T>C) C allele is associated with an increased risk of atorvastatin-induced myopathy. Puccetti, et al. (2010) (85) Brunham, et al. (2012) (86) Santos, et al. (2012) (87) Hou, et al. (2015) (88) Hubacek, et al. (2015) (89) Mirosevic, et al. (2015) (90) Liu, et al. (2017) (91) Xiang, et al. (2018) (92) Du, et', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='Dou Y et al. Meta-analysis of the SLCO1B1 c.521T>C variant reveals slight influence on the lipid-lowering efficacy of statins. Ann Lab Med 2015;35:329-35.8. de Keyser CE et al. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics 2014;24:43-51.9. Carr DF et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the Clinical Practice Research Datalink. Clin Pharmacol Ther 2013;94:695-701.', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='14 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0   FIGURE S1. PHARMACOKINETIC IMPACT OF RS4149056 GENOTYPE FOR SEVERAL STATINS.  Effect of the SLCO1B1 c.521T>C variant (rs4149056) on plasma exposure (i.e., area under the concentration-time curve) for different statins, CC vs TT. This summary figure represents a composite of single-dose data from the following references: Pasanen et al (4), Ieiri et al (18), Lee et al. (77), Niemi et al (78), Pasanen et al (79), Choi et al (80), Deng et al (17), Ho et al (81).', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='of increased atorvastatin response. Int J Mol Sci 2011;12:5815-27.14. Puccetti L et al. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 2010;211:28-9.15. Lee YJ et al. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Int J Clin Pharmacol Ther 2010;48:36-45.16. Voora D et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16.17. Mega JL et al. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 2009;29:1310-5.18. He YJ et al. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta 2009;405:49-52.19. Pasanen MK et al. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='18 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  Du, et al. (2018) (93) Fluvastatin Clinical Presence of the SLCO1B1*14 allele is associated with enhanced lipid-lowering efficacy for fluvastatin. Couvert, et al. (2008) (115) Moderate Clinical The SLCO1B1 rs4149056 (c.521T>C) C variant is associated with decreased lipid- lowering response to fluvastatin. Couvert, et al. (2008) (115) Meyer, et al. (2015) (110) Xiang, et al. (2018) (116) Weak In vitro The uptake of fluvastatin was not influenced by SLCO1B1 rs4149056 (c.521T>C) at concentrations >1 uM Deng, et al. (2008) (117) Xiang, et al. (2020 (118) Moderate In vitro The SLCO1B1 rs4149056 (c.521T>C) C variant is associated with reduced uptake of both fluvastatin enantiomers (3R,5S-fluvastatin and 3S,5R-fluvastatin). Hirvensalo, et al. (2019) (119) Moderate Clinical Fluvastatin PK did not differ between subjects with different SLCO1B1 rs4149056 (c.521T>C) genotypes. Niemi, et al. (2006) (120) Zhou, et al.', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='atorvastatin,,,,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,No CDS,n/a', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='test information by providers and is available at http://www.ncbi.nlm.nih.gov/gtr/.   LINKING GENETIC VARIABILITY TO VARIABILITY IN DRUG-RELATED PHENOTYPES  SLCO1B1. Both SLCO1B1 decreased and poor function phenotypes are associated with increased exposure for most statins, with greater effects of poor function phenotypes.  Effects on exposure also vary by statin type (Figure S1). Therefore, the risk of SAMS varies based on statin type and statin dose. For simvastatin, the evidence linking SAMS to SLCO1B1 rs4149056 (c.521T>C) is of high quality, and this association has been reproduced in retrospective studies of randomized trials and clinical practice-based cohorts (Table S1). This variant is present in several SLCO1B1 star alleles including the relatively common SLCO1B1*5 and *15 alleles. Although the association of rs4149056 with myopathy varies by statin, there is evidence supporting the role of SLCO1B1 variants in the systemic clearance of all statins (3) (Table S1).  Pasanen et', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 38  (111) Prado, Y., Saavedra, N., Zambrano, T., Lagos, J., Rosales, A. & Salazar, L.A. SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals. Int J Mol Sci  16, 20609-19 (2015). (112) Mladenovska, K. et al. Influence of SLCO1B1 polymorphisms on atorvastatin efficacy and safety in Macedonian subjects. Pharmazie  72, 288-95 (2017). (113) de Keyser, C.E. et al. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics  24, 43-51 (2014). (114) Kadam, P., Ashavaid, T.F., Ponde, C.K. & Rajani, R.M. Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population. J Clin Pharm Ther  41, 329-33 (2016). (115) Couvert, P. et al. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='Cardiol 2009;54:1609-16.16. Pasanen MK et al. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenet Genomics 2008;18:921-6.17. SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy -- a genomewide study. N Engl J Med 2008;359:789-99.18. Pasanen MK et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006;16:873-9.19. Ramsey LB et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther 2014;96:423-8.20. SmPC Zocor.Date 18-05-2020CYP2C9 *1/*2: siponimod7160NO action is required for this gene-drug interaction.The genetic variation can slightly increase the exposure to siponimod. However, the effect is too small to expect any impact on efficacy or adverse effects.Literature:1. Gardin A et al. Siponimod', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: A SLCO1B1 *1/*20 diplotype would have which phenotype?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *20/*20 display a SLC01B1 Increased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*40 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*30 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*27 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*28 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*32 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*20 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*25 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *19/*20 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *16/*20 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: Wht phenotype is associated with SLCO1B1 *14/*14 diplotype?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *14/*27 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*44 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*34 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*26 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*41 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*28 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*25 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*33 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*24 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: What is the associated phenotype for the CYP2C9 *2/*15 diplotype?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *2/*9  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*15  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*16  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*16  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*16  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *14/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: List  SLCO1B1 diplotypes with a "normal function" phenotype.
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *1/*20 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*14 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*37 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*37 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*37 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='\ufeffPatients with the SLCO1B1 Diplotype *1/*1 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *37/*37 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*20 display a SLC01B1 Increased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*20 display a SLC01B1 Increased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*20 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My patient has ABCG2 decreased function. Can you tell me what variant he has?
retrieved_docs: [Document(page_content="Patients with ABCG2 Diplotype 'rs2231142 reference (G)/rs2231142 variant (T)' display ABCG2 Decreased Function Phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n", metadata={'link': '', 'source': 'ABCG2 Diplotype Phenotype Mapping'}), Document(page_content="Patients with ABCG2 Diplotype 'rs2231142 variant (T)/rs2231142 variant (T)' display ABCG2 Poor Function Phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.", metadata={'link': '', 'source': 'ABCG2 Diplotype Phenotype Mapping'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='one decreased function allele (rs2231142; c.421C>A) has ABCG2 \ndecreased function, and an individual with two decreased \nfunction alleles has ABCG2 poor function. rs2231142 can be \ngenotyped alone (e.g., polymerase chain reaction–  based single \nSNP assay) or multiplexed on a variety of array-  based platforms. \nVarious commercial genotyping platforms include rs2231142 in \npanels of pharmacogenetic variants.12Table 1 Assignment of predicted SLCO1B1, ABCG2, and CYP2C9 likely phenotype based on genotype\nGene Phenotypea,bActivity score \n(if applicable) Genotype Examples of diplotypes\nSLCO1B1 Increased function n/a An individual carrying two increased \nfunction alleles*14/*14\nNormal function n/a An individual carrying two normal \nfunction alleles or one normal plus one \nincreased function allele*1/*1, *1/*14\nDecreased function n/a An individual carrying one normal or \nincreased function allele plus one no \nfunction allele*1/*5, *1/*15,', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 decreased function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 increased function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My patient has rs2231142 variant (T) in the  ABCG2 gene. What is her phenotype?
retrieved_docs: [Document(page_content="Patients with ABCG2 Diplotype 'rs2231142 variant (T)/rs2231142 variant (T)' display ABCG2 Poor Function Phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.", metadata={'link': '', 'source': 'ABCG2 Diplotype Phenotype Mapping'}), Document(page_content="Patients with ABCG2 Diplotype 'rs2231142 reference (G)/rs2231142 variant (T)' display ABCG2 Decreased Function Phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n", metadata={'link': '', 'source': 'ABCG2 Diplotype Phenotype Mapping'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='one decreased function allele (rs2231142; c.421C>A) has ABCG2 \ndecreased function, and an individual with two decreased \nfunction alleles has ABCG2 poor function. rs2231142 can be \ngenotyped alone (e.g., polymerase chain reaction–  based single \nSNP assay) or multiplexed on a variety of array-  based platforms. \nVarious commercial genotyping platforms include rs2231142 in \npanels of pharmacogenetic variants.12Table 1 Assignment of predicted SLCO1B1, ABCG2, and CYP2C9 likely phenotype based on genotype\nGene Phenotypea,bActivity score \n(if applicable) Genotype Examples of diplotypes\nSLCO1B1 Increased function n/a An individual carrying two increased \nfunction alleles*14/*14\nNormal function n/a An individual carrying two normal \nfunction alleles or one normal plus one \nincreased function allele*1/*1, *1/*14\nDecreased function n/a An individual carrying one normal or \nincreased function allele plus one no \nfunction allele*1/*5, *1/*15,', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='facilitates the export of compounds into the extracellular space. \nThe ABCG2  gene locus spans over 66\xa0kb on chromosome 4 (Chr \n4q22.1). The common variant p.Q141K (c.421C>A, rs2231142) \nhas been studied extensively; the minor A allele is associated \nwith 30–  40% reduced protein expression compared with the \nreference allele and with increased plasma levels of rosuvastatin \n(Table\xa0 S2) (ABCG2  Allele  Definition Table and ABCG2  \nAllele  Functionality Table6,7). Differences in allele frequencies \nhave been observed across multiple geographically, racially, and \nethnically diverse groups ( ABCG2  Allele Frequency Table6,7).\nCYP2C9.  The cytochrome P450 2C9 (CYP2C9) enzyme \ncontributes to the phase I metabolism of many drugs. CYP2C9  \nis one of the CYP2C  genes clustered in a 500-  kb region on 10q24 \n(Chr 10q23.33). The CYP2C9  gene is highly polymorphic, with \nat least 71 variant alleles ( CYP2C9 Allele Definition Table6,7,9).', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have SLCO1B1 normal function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='22 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  TABLE S2.  EVIDENCE LINKING ABCG2 GENOTYPE WITH STATIN PHENOTYPE Type of experimental model (in vitro, in vivo preclinical, or clinical) Major Findings References  Level of Evidence Clinical ABCG2 rs2231142 (c.421C>A) CA genotype is found to be more frequent in statin-intolerant cases. Shek, et al. (2017) (134)  Weak Clinical ABCG2 rs2231142 (c.421C>A) is associated with simvastatin-induced liver symptoms. Shek, et al. (2018) (162)  Moderate  Clinical ABCG2 rs2231142 (c.421C>A) may be associated with statin-induced muscle symptoms. Chan, et al. (2019) (139) Weak Clinical ABCG2 rs2231142 (c.421C>A) A allele carriers had higher AUC(0-t) and Cmax of simvastatin acid as compared with those carrying the CC genotype. It did not affect simvastatin lactone concentration. Keskitalo, et al. (2009) (163) Birmingham, et al. (2015) (101) Choi, et al. (2015) (142)  Weak Clinical ABCG2 rs2231142 (c.421C>A) is not', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'})]

question: My test results show rs2231142 variant and reference on ABCG2 gene. What does this mean?
retrieved_docs: [Document(page_content="Patients with ABCG2 Diplotype 'rs2231142 reference (G)/rs2231142 variant (T)' display ABCG2 Decreased Function Phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n", metadata={'link': '', 'source': 'ABCG2 Diplotype Phenotype Mapping'}), Document(page_content="Patients with ABCG2 Diplotype 'rs2231142 variant (T)/rs2231142 variant (T)' display ABCG2 Poor Function Phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.", metadata={'link': '', 'source': 'ABCG2 Diplotype Phenotype Mapping'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have SLCO1B1 normal function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='one decreased function allele (rs2231142; c.421C>A) has ABCG2 \ndecreased function, and an individual with two decreased \nfunction alleles has ABCG2 poor function. rs2231142 can be \ngenotyped alone (e.g., polymerase chain reaction–  based single \nSNP assay) or multiplexed on a variety of array-  based platforms. \nVarious commercial genotyping platforms include rs2231142 in \npanels of pharmacogenetic variants.12Table 1 Assignment of predicted SLCO1B1, ABCG2, and CYP2C9 likely phenotype based on genotype\nGene Phenotypea,bActivity score \n(if applicable) Genotype Examples of diplotypes\nSLCO1B1 Increased function n/a An individual carrying two increased \nfunction alleles*14/*14\nNormal function n/a An individual carrying two normal \nfunction alleles or one normal plus one \nincreased function allele*1/*1, *1/*14\nDecreased function n/a An individual carrying one normal or \nincreased function allele plus one no \nfunction allele*1/*5, *1/*15,', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'})]

question: My genetic test result shows CYP2C9 *12 *38 diplotype. What is the meaning of this?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *38/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *38/*44  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *12/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *38/*61  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *38/*46  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *37/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *16/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *23/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: What are the genotypes for CYP2C9 Normal Metabolizer impacting statins?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *16/*45  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *16/*24  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*6  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*8  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *24/*28  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *13/*16  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *4/*6  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *25/*46  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *42/*46  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *14/*42  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: My patient has *1/*7 diplotype in the CYP2C9 gene. Does this have a known phenotype?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *1/*7  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*27  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*67  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*17  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*72  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *7/*27  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*6  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*57  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *7/*17  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*47  display a CYP2C9 Indeterminate phenotype with an activity score of n/a. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: My patient has *3/*31 diplotype in the CYP2C9 gene. What is the phenotype?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *3/*31  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*9  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*30  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*29  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*26  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*23  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*37  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: What phenotype is associated with the SLCO1B1 *1/*37 diplotype?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *37/*37 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*37 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *37/*38 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *37/*41 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*37 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *37/*45 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *36/*37 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *28/*37 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *19/*37 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *26/*37 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: Can you tell me the phenotype for the CYP2C9 *1/*3 diplotype?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *3/*9  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*3  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*33  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*33  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*39  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *23/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: What is the phenotype for the SLCO1B1 *14/*20 diplotype?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *14/*20 display a SLC01B1 Increased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*20 display a SLC01B1 Increased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*14 display a SLC01B1 Increased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*28 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*20 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*19 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*27 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*40 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*37 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*15 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My patient's PGx result indicates CYP2C9 *1/*6 diplotype. What does this mean?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *6/*9  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*6  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*61  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*16  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *16/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *46/*61  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *16/*61  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*46  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*33  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: What phenotype is associated with the ABCG2 rs2231142 variant on both alleles?
retrieved_docs: [Document(page_content="Patients with ABCG2 Diplotype 'rs2231142 variant (T)/rs2231142 variant (T)' display ABCG2 Poor Function Phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.", metadata={'link': '', 'source': 'ABCG2 Diplotype Phenotype Mapping'}), Document(page_content="Patients with ABCG2 Diplotype 'rs2231142 reference (G)/rs2231142 variant (T)' display ABCG2 Decreased Function Phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n", metadata={'link': '', 'source': 'ABCG2 Diplotype Phenotype Mapping'}), Document(page_content='one decreased function allele (rs2231142; c.421C>A) has ABCG2 \ndecreased function, and an individual with two decreased \nfunction alleles has ABCG2 poor function. rs2231142 can be \ngenotyped alone (e.g., polymerase chain reaction–  based single \nSNP assay) or multiplexed on a variety of array-  based platforms. \nVarious commercial genotyping platforms include rs2231142 in \npanels of pharmacogenetic variants.12Table 1 Assignment of predicted SLCO1B1, ABCG2, and CYP2C9 likely phenotype based on genotype\nGene Phenotypea,bActivity score \n(if applicable) Genotype Examples of diplotypes\nSLCO1B1 Increased function n/a An individual carrying two increased \nfunction alleles*14/*14\nNormal function n/a An individual carrying two normal \nfunction alleles or one normal plus one \nincreased function allele*1/*1, *1/*14\nDecreased function n/a An individual carrying one normal or \nincreased function allele plus one no \nfunction allele*1/*5, *1/*15,', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='facilitates the export of compounds into the extracellular space. \nThe ABCG2  gene locus spans over 66\xa0kb on chromosome 4 (Chr \n4q22.1). The common variant p.Q141K (c.421C>A, rs2231142) \nhas been studied extensively; the minor A allele is associated \nwith 30–  40% reduced protein expression compared with the \nreference allele and with increased plasma levels of rosuvastatin \n(Table\xa0 S2) (ABCG2  Allele  Definition Table and ABCG2  \nAllele  Functionality Table6,7). Differences in allele frequencies \nhave been observed across multiple geographically, racially, and \nethnically diverse groups ( ABCG2  Allele Frequency Table6,7).\nCYP2C9.  The cytochrome P450 2C9 (CYP2C9) enzyme \ncontributes to the phase I metabolism of many drugs. CYP2C9  \nis one of the CYP2C  genes clustered in a 500-  kb region on 10q24 \n(Chr 10q23.33). The CYP2C9  gene is highly polymorphic, with \nat least 71 variant alleles ( CYP2C9 Allele Definition Table6,7,9).', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='Clinical ABCG2 rs2231142 (c.421C>A) A allele is not significantly associated with an increased risk of atorvastatin-induced liver tox. Fukunaga, et al. (2016) (98) Weak Clinical ABCG2 rs2231142 (c.421C>A) A allele is significantly associated with an increased risk of atorvastatin-induced adverse events. Mirosevic Skvrce, et al. (2015) (90) Moderate', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 Diplotypes: *1/*2, *1/*3, *1/*4, *1/*6, *1/*7, *1/*8, *1/*10, *1/*11, *1/*12, *1/*13, *1/*16, *1/*19, *1/*24, *1/*25, *1/*26, *1/*27, *1/*28, *1/*29, *1/*30, *1/*32, *1/*33, *1/*34, *1/*36, *1/*38, *1/*39, *1/*40, *1/*41, *1/*42, *1/*43, *1/*44, *1/*45, *2/*2, *2/*3, *2/*4, *2/*6, *2/*7, *2/*8, *2/*10, *2/*11, *2/*12, *2/*13, *2/*14, *2/*16, *2/*19, *2/*20, *2/*24, *2/*25, *2/*26, *2/*27, *2/*28, *2/*29, *2/*30, *2/*32, *2/*33, *2/*34, *2/*36, *2/*37, *2/*38, *2/*39, *2/*40, *2/*41, *2/*42, *2/*43, *2/*44, *2/*45, *3/*3, *3/*4, *3/*6, *3/*7, *3/*8, *3/*10, *3/*11, *3/*12, *3/*13, *3/*14, *3/*16, *3/*19, *3/*20, *3/*24, *3/*25, *3/*26, *3/*27, *3/*28, *3/*29, *3/*30, *3/*32, *3/*33, *3/*34, *3/*36, *3/*37, *3/*38, *3/*39, *3/*40, *3/*41, *3/*42, *3/*43, *3/*44, *3/*45, *4/*4, *4/*6, *4/*7, *4/*8, *4/*10, *4/*11, *4/*12, *4/*13, *4/*14, *4/*16, *4/*19, *4/*20, *4/*24, *4/*25, *4/*26, *4/*27, *4/*28, *4/*29, *4/*30, *4/*32, *4/*33, *4/*34, *4/*36, *4/*37, *4/*38, *4/*39, *4/*40, *4/*41, *4/*42, *4/*43, *4/*44, *4/*45, *6/*6, *6/*7, *6/*8, *6/*10, *6/*11, *6/*12, *6/*13, *6/*14, *6/*16, *6/*19, *6/*20, *6/*24, *6/*25, *6/*26, *6/*27, *6/*28, *6/*29, *6/*30, *6/*32, *6/*33, *6/*34, *6/*36, *6/*37, *6/*38, *6/*39, *6/*40, *6/*41, *6/*42, *6/*43, *6/*44, *6/*45, *7/*7, *7/*8, *7/*10, *7/*11, *7/*12, *7/*13, *7/*14, *7/*16, *7/*19, *7/*20, *7/*24, *7/*25, *7/*26, *7/*27, *7/*28, *7/*29, *7/*30, *7/*32, *7/*33, *7/*34, *7/*36, *7/*37, *7/*38, *7/*39, *7/*40, *7/*41, *7/*42, *7/*43, *7/*44, *7/*45, *8/*8, *8/*10, *8/*11, *8/*12, *8/*13, *8/*14, *8/*16, *8/*19, *8/*20, *8/*24, *8/*25, *8/*26, *8/*27, *8/*28, *8/*29, *8/*30, *8/*32, *8/*33, *8/*34, *8/*36, *8/*37, *8/*38, *8/*39, *8/*40, *8/*41, *8/*42, *8/*43, *8/*44, *8/*45, *10/*10, *10/*11, *10/*12, *10/*13, *10/*14, *10/*16, *10/*19, *10/*20, *10/*24, *10/*25, *10/*26, *10/*27, *10/*28, *10/*29, *10/*30, *10/*32, *10/*33, *10/*34, *10/*36, *10/*37, *10/*38, *10/*39, *10/*40, *10/*41, *10/*42, *10/*43, *10/*44, *10/*45, *11/*11, *11/*12, *11/*13, *11/*14, *11/*16, *11/*19, *11/*20, *11/*24, *11/*25, *11/*26, *11/*27, *11/*28, *11/*29, *11/*30, *11/*32, *11/*33, *11/*34, *11/*36, *11/*37, *11/*38, *11/*39, *11/*40, *11/*41, *11/*42, *11/*43, *11/*44, *11/*45, *12/*12, *12/*13, *12/*14, *12/*16, *12/*19, *12/*20, *12/*24, *12/*25, *12/*26, *12/*27, *12/*28, *12/*29, *12/*30, *12/*32, *12/*33, *12/*34, *12/*36, *12/*37, *12/*38, *12/*39, *12/*40, *12/*41, *12/*42, *12/*43, *12/*44, *12/*45, *13/*13, *13/*14, *13/*16, *13/*19, *13/*20, *13/*24, *13/*25, *13/*26, *13/*27, *13/*28, *13/*29, *13/*30, *13/*32, *13/*33, *13/*34, *13/*36, *13/*37, *13/*38, *13/*39, *13/*40, *13/*41, *13/*42, *13/*43, *13/*44, *13/*45, *14/*16, *14/*19, *14/*24, *14/*25, *14/*26, *14/*27, *14/*28, *14/*29, *14/*30, *14/*32, *14/*33, *14/*34, *14/*36, *14/*38, *14/*39, *14/*40, *14/*41, *14/*42, *14/*43, *14/*44, *14/*45, *16/*16, *16/*19, *16/*20, *16/*24, *16/*25, *16/*26, *16/*27, *16/*28, *16/*29, *16/*30, *16/*32, *16/*33, *16/*34, *16/*36, *16/*37, *16/*38, *16/*39, *16/*40, *16/*41, *16/*42, *16/*43, *16/*44, *16/*45, *19/*19, *19/*20, *19/*24, *19/*25, *19/*26, *19/*27, *19/*28, *19/*29, *19/*30, *19/*32, *19/*33, *19/*34, *19/*36, *19/*37, *19/*38, *19/*39, *19/*40, *19/*41, *19/*42, *19/*43, *19/*44, *19/*45, *20/*24, *20/*25, *20/*26, *20/*27, *20/*28, *20/*29, *20/*30, *20/*32, *20/*33, *20/*34, *20/*36, *20/*38, *20/*39, *20/*40, *20/*41, *20/*42, *20/*43, *20/*44, *20/*45, *24/*24, *24/*25, *24/*26, *24/*27, *24/*28, *24/*29, *24/*30, *24/*32, *24/*33, *24/*34, *24/*36, *24/*37, *24/*38, *24/*39, *24/*40, *24/*41, *24/*42, *24/*43, *24/*44, *24/*45, *25/*25, *25/*26, *25/*27, *25/*28, *25/*29, *25/*30, *25/*32, *25/*33, *25/*34, *25/*36, *25/*37, *25/*38, *25/*39, *25/*40, *25/*41, *25/*42, *25/*43, *25/*44, *25/*45, *26/*26, *26/*27, *26/*28, *26/*29, *26/*30, *26/*32, *26/*33, *26/*34, *26/*36, *26/*37, *26/*38, *26/*39, *26/*40, *26/*41, *26/*42, *26/*43, *26/*44, *26/*45, *27/*27, *27/*28, *27/*29, *27/*30, *27/*32, *27/*33, *27/*34, *27/*36, *27/*37, *27/*38, *27/*39, *27/*40, *27/*41, *27/*42, *27/*43, *27/*44, *27/*45, *28/*28, *28/*29, *28/*30, *28/*32, *28/*33, *28/*34, *28/*36, *28/*37, *28/*38, *28/*39, *28/*40, *28/*41, *28/*42, *28/*43, *28/*44, *28/*45, *29/*29, *29/*30, *29/*32, *29/*33, *29/*34, *29/*36, *29/*37, *29/*38, *29/*39, *29/*40, *29/*41, *29/*42, *29/*43, *29/*44, *29/*45, *30/*30, *30/*32, *30/*33, *30/*34, *30/*36, *30/*37, *30/*38, *30/*39, *30/*40, *30/*41, *30/*42, *30/*43, *30/*44, *30/*45, *32/*32, *32/*33, *32/*34, *32/*36, *32/*37, *32/*38, *32/*39, *32/*40, *32/*41, *32/*42, *32/*43, *32/*44, *32/*45, *33/*33, *33/*34, *33/*36, *33/*37, *33/*38, *33/*39, *33/*40, *33/*41, *33/*42, *33/*43, *33/*44, *33/*45, *34/*34, *34/*36, *34/*37, *34/*38, *34/*39, *34/*40, *34/*41, *34/*42, *34/*43, *34/*44, *34/*45, *36/*36, *36/*37, *36/*38, *36/*39, *36/*40, *36/*41, *36/*42, *36/*43, *36/*44, *36/*45, *37/*38, *37/*39, *37/*40, *37/*41, *37/*42, *37/*43, *37/*44, *37/*45, *38/*38, *38/*39, *38/*40, *38/*41, *38/*42, *38/*43, *38/*44, *38/*45, *39/*39, *39/*40, *39/*41, *39/*42, *39/*43, *39/*44, *39/*45, *40/*40, *40/*41, *40/*42, *40/*43, *40/*44, *40/*45, *41/*41, *41/*42, *41/*43, *41/*44, *41/*45, *42/*42, *42/*43, *42/*44, *42/*45, *43/*43, *43/*44, *43/*45, *44/*44, *44/*45, *45/*45",SLCO1B1 Indeterminate,,Post-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='22 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  TABLE S2.  EVIDENCE LINKING ABCG2 GENOTYPE WITH STATIN PHENOTYPE Type of experimental model (in vitro, in vivo preclinical, or clinical) Major Findings References  Level of Evidence Clinical ABCG2 rs2231142 (c.421C>A) CA genotype is found to be more frequent in statin-intolerant cases. Shek, et al. (2017) (134)  Weak Clinical ABCG2 rs2231142 (c.421C>A) is associated with simvastatin-induced liver symptoms. Shek, et al. (2018) (162)  Moderate  Clinical ABCG2 rs2231142 (c.421C>A) may be associated with statin-induced muscle symptoms. Chan, et al. (2019) (139) Weak Clinical ABCG2 rs2231142 (c.421C>A) A allele carriers had higher AUC(0-t) and Cmax of simvastatin acid as compared with those carrying the CC genotype. It did not affect simvastatin lactone concentration. Keskitalo, et al. (2009) (163) Birmingham, et al. (2015) (101) Choi, et al. (2015) (142)  Weak Clinical ABCG2 rs2231142 (c.421C>A) is not', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='8 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  to higher allele frequencies of the reduced function ABCG2 polymorphism, c.421G>A (rs2231142) (25); however, other factors may contribute to higher rosuvastatin levels in Asians (26). The effect of the ABCG2 polymorphism, rs2231142 (c.421C>A), has also been studied for its association with pharmacokinetic, toxicity or efficacy with other statins, such as atorvastatin, pitavastatin, fluvastatin and lovastatin (Table S2).  Except for fluvastatin, in which a single study showed a clear association of rs2231142 with exposure, the evidence for association of ABCG2 genetic variants with exposure, response or toxicity to other statins is considered weak to moderate primarily because of small sample sizes or variation in results among studies (Table S2).   CYP2C9. Genetic variations in CYP2C9 are associated with increased exposure to fluvastatin (Table S3), but the pharmacokinetics or pharmacodynamics of other statins', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='Clinical In vitro study showed that ABCG2 affect atorvastatin transport. Keskitalo, et al. (2009) (21) High   Clinical ABCG2 rs2231142 (c.421C>A) is not associated with atorvastatin response. Prado, et al. (2018) (181) Moderate Clinical ABCG2 rs2231142 (c.421C>A) is not associated with decreased clearance of pravastatin. Ho, et al. (2007) (182) Keskitalo, et al. (2009) (163) Lu, et al. (2016) (183) Moderate In vitro Pitavastatin acid is a substrate of ABCG2, whereas the lactone form is not. ABCG2 is involved in the biliary excretion of pitavastatin. Fujino, et al. (2005) (184) Hirano, et al. (2005) (185) Moderate Clinical ABCG2 rs2231142 (c.421C>A) is not significantly associated with concentration of pitavastatin. Ieiri, et al. (2007) (127) Oh, et al. (2013) (128) Moderate Clinical ABCG2 rs2231142 (c.421C>A) AA genotype is associated with higher fluvastatin AUC. Keskitalo, et al. (2009) (163) High Clinical ABCG2 rs2231142 (c.421C>A) is associated with greater odds of developing', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='plasma variability: limited role for SLCO1B1 c.521T>C and ABCG2 c.421A>C. Pharmacogenomics J  19, 240-8 (2019). (179) Zhang, D. et al. Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin. Eur J Clin Pharmacol  76, 939-46 (2020). (180) Tsamandouras, N., Guo, Y., Wendling, T., Hall, S., Galetin, A. & Aarons, L. Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population. Pharmacogenet Genomics  27, 27-38 (2017). (181) Prado, Y., Zambrano, T. & Salazar, L.A. Transporter genes ABCG2 rs2231142 and ABCB1 rs1128503 polymorphisms and atorvastatin response in Chilean subjects. J Clin Pharm Ther  43, 87-91 (2018). (182) Ho, R.H. et al. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics  17, 647-56 (2007).', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'})]

question: My patient's test results show *12/*23 on SLCOB1. What does this mean?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *12/*12 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*33 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*13 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*43 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*27 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*28 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*24 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*25 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*32 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: What does SLCO1B1 *1 *1 mean?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *1/*20 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*14 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='\ufeffPatients with the SLCO1B1 Diplotype *1/*1 display a SLC01B1 Normal Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*31 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*23 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*9 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*5 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*33 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*8 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *31/*33 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My PGx test results say that I have CYP2C9 *2 / *13 genotype, before I meet with my doctor, I would like to get more information on this.
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *2/*9  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*13  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*12  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*11  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*44  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*33  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*37  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*16  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: What are the implications of having a *2/*33 diplotype in the gene CYP2C9?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *23/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *33/*37  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*33  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *23/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*9  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *33/*46  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: What are therapy implications for a patient with SLCO1B1 *11/*46 diplotype?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *11/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *11/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *13/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *42/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *41/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *44/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *45/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *26/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*46 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: What does CYP2C9 *1/*9 mean?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *9/*39  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*33  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*45  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*13  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*29  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*42  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*25  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*15  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*24  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: My genetic test results indicate that I might be at risk of muscle pain if I take some cholesterol medications because I have SLCO1B1 *1/*9 diplotype. I would like to understand this better.
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *9/*25 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*16 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*27 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*42 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*9 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *13/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *7/*15 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *16/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My patient has a SLCO1B1 *2/*31 diplotype. What are therapeutic implications?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *2/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*48 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *31/*42 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *30/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *32/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *26/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *28/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: What are CPIC guidelines for SLCO1B1 *1/*14 genotype?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *14/*33 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*16 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*28 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*34 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*38 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*27 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*41 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*40 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*32 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *14/*36 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: Are there any therapeutic guidelines for CYP2C9 *1 *2 diplotype?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *1/*9  display a CYP2C9 Normal Metabolizer phenotype with an activity score of 2.0. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*2  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*9  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*3  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*12  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='\ufeffPatients with the CYP2C9 Diplotype *1/*1  display a CYP2C9 Normal Metabolizer phenotype with an activity score of 2.0. The corresponding EHR notation for this diplotype categorizes it as Normal/Routine/Low Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*61  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*13  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*2  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: What does having alleles *4/*44 in the SLCO1B1 gene mean?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *4/*44 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *44/*48 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *44/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *4/*4 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *4/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *44/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *4/*48 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *4/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *44/*44 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *4/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: What is the metabolizer phenotype for CYP2C9 *2/*45 genotype?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *45/*46  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *45/*45  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *45/*50  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *45/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *45/*55  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *45/*52  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*45  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *44/*45  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *37/*45  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *42/*46  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: What does CYP2C9 *4 *61 do?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *43/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *42/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *39/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *45/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *52/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *24/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *6/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *33/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *25/*61  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: What is the EHR notation for SLCO1B1 *49/*49?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *39/*39 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *39/*44 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *39/*43 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *39/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *39/*41 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *39/*45 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *37/*39 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *43/*45 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *37/*43 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *42/*44 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: What does a CYP2C9 *3/*5 diplotype indicate?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *5/*9  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*5  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*31  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*23  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *3/*31  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*55  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *5/*5  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *1/*5  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *5/*23  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: My patient's genetic test shows SLCO1B1 *27/*49. What gene is this associated with?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *27/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *27/*46 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *27/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *27/*48 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *27/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *23/*27 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *26/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *29/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *7/*47 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *37/*49 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: Can you explain the SLCO1B1 *34/*42 diplotype?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *34/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *34/*44 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *42/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *34/*40 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *33/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *38/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *32/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *36/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *40/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *28/*42 display a SLC01B1 Indeterminate phenotype. The corresponding EHR notation for this diplotype categorizes it as none.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My genetic test indicates a CYP2C9 *2/*8 genotype. What gene is this related to?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *2/*9  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *8/*8  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*8  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *8/*9  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *8/*28  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *8/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *9/*26  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *28/*38  display a CYP2C9 Intermediate Metabolizer phenotype with an activity score of 1.0. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: Is there any difference between SLCO1B1 decreased function and SLCO1B1 possible decreased function for simvastatin dosage?
retrieved_docs: [Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='simvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='is not an option:1. Avoid simvastatin doses exceeding 40 mg/day2. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Xiang Q et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J 2018;18:721-9.2. Wu X et al. Associations of the SLCO1B1 polymorphisms with hepatic function, baseline lipid levels, and lipid-lowering response to simvastatin in patients with hyperlipidemia. Clin Appl Thromb Hemost2018;24:240S-247S.3. Kitzmiller JP et al. Candidate-gene study of functional polymorphisms in SLCO1B1 and CYP3A4/5 and the cholesterol-lowering response to simvastatin. Clin Transl Sci 2017;10:172-7.4. Jiang J et al. Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: a meta-analysis. Springerplus 2016;5:1368.5. Hou Q et al. Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='Clinical SLCO1B1*17 is associated with an increased risk of simvastatin-induced myopathy. Chan, et al. (2019) (139)   Weak Clinical SLCO1B1 rs4149056 C (c.521T>C) polymorphism markedly affects the pharmacokinetics of active simvastatin acid, but has no significant effect on parent simvastatin. Pasanen, et al. (2006) (4) Zhou, et al. (2013) (140) Tsamandouras, et al. (2014) (141) High', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals. Eur J Clin Pharmacol 2013;69:1269-74.9. Carr DF et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the Clinical Practice Research Datalink. Clin Pharmacol Ther 2013;94:695-701.10. Francesca Notarangelo M et al. Genetic predisposition to atorvastatin-induced myopathy: a case report. J Clin Pharm Ther 2012;37:604-6.11. Brunham LR et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 2012;12:233-7.12. Santos PC et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol 2012;68:273-9.13. Rodrigues AC et al. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response. Int J Mol Sci', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='with normal function \nand decreased function; \ntypical myopathy risk with \ndoses ≤20\xa0mgPrescribe ≤20\xa0mg as a starting dose and adjust \ndoses of rosuvastatin based on disease-  specific \nand population-  specific guidelines If dose >20\xa0mg \nneeded for desired efficacy, consider combination \ntherapy (i.e., rosuvastatin plus nonstatin guideline-  \ndirected medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and Asian ancestry should be \nevaluated prior to initiating a statin. The \neffects of drug–  drug interactions may be \nmore pronounced, resulting in a higher risk \nof myopathy\nSimvastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased simvastatin \nacid exposure as \ncompared with normal \nfunction; increased risk \nof myopathyPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If simvastatin therapy is', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'})]

question: How does SLCO1B1 decreased function affect simvastatin dosage ?
retrieved_docs: [Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Clinical SLCO1B1*17 is associated with an increased risk of simvastatin-induced myopathy. Chan, et al. (2019) (139)   Weak Clinical SLCO1B1 rs4149056 C (c.521T>C) polymorphism markedly affects the pharmacokinetics of active simvastatin acid, but has no significant effect on parent simvastatin. Pasanen, et al. (2006) (4) Zhou, et al. (2013) (140) Tsamandouras, et al. (2014) (141) High', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='with normal function \nand decreased function; \ntypical myopathy risk with \ndoses ≤20\xa0mgPrescribe ≤20\xa0mg as a starting dose and adjust \ndoses of rosuvastatin based on disease-  specific \nand population-  specific guidelines If dose >20\xa0mg \nneeded for desired efficacy, consider combination \ntherapy (i.e., rosuvastatin plus nonstatin guideline-  \ndirected medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and Asian ancestry should be \nevaluated prior to initiating a statin. The \neffects of drug–  drug interactions may be \nmore pronounced, resulting in a higher risk \nof myopathy\nSimvastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased simvastatin \nacid exposure as \ncompared with normal \nfunction; increased risk \nof myopathyPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If simvastatin therapy is', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='is not an option:1. Avoid simvastatin doses exceeding 40 mg/day2. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Xiang Q et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J 2018;18:721-9.2. Wu X et al. Associations of the SLCO1B1 polymorphisms with hepatic function, baseline lipid levels, and lipid-lowering response to simvastatin in patients with hyperlipidemia. Clin Appl Thromb Hemost2018;24:240S-247S.3. Kitzmiller JP et al. Candidate-gene study of functional polymorphisms in SLCO1B1 and CYP3A4/5 and the cholesterol-lowering response to simvastatin. Clin Transl Sci 2017;10:172-7.4. Jiang J et al. Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: a meta-analysis. Springerplus 2016;5:1368.5. Hou Q et al. Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='leads to reduced simvastatin transport to the liver, which increases the simvastatin plasma concentration and therefore the risk of side effects.1. Choose an alternativeConsider any additional risk factors for statin-induced myopathy.Atorvastatin is affected less severely by the SLCO1B1 gene variation, but is also affected by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Use of atorvastatin is not recommended for patientswith additional risk factors for statin-induced myopathy.Rosuvastatin and pravastatin are influenced to a lesser extent by the SLCO1B1 gene variation. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.Fluvastatin is not significantly influenced by the SLCO1B1 gene variation or CYP3A4 inhibitors.Literature:1. Xiang Q et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J 2018;18:721-9.2. Wu X et al. Associations of the SLCO1B1', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'})]

question: Will my patient's genetic status for the SLCO1B1 gene affect their atorvastatin prescription?
retrieved_docs: [Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='of increased atorvastatin response. Int J Mol Sci 2011;12:5815-27.14. Puccetti L et al. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 2010;211:28-9.15. Lee YJ et al. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Int J Clin Pharmacol Ther 2010;48:36-45.16. Voora D et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16.17. Mega JL et al. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 2009;29:1310-5.18. He YJ et al. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta 2009;405:49-52.19. Pasanen MK et al. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='T.A., Naveed, A.K., Farooqi, Z.R. & Khan, S. Effects of two functionally important SLCO1B1 gene polymorphisms on pharmacokinetics of atorvastatin. Pak J Pharm Sci  30, 1363-70 (2017). (104) Wang, Y. et al. The effect of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Chinese people. Pharmazie  72, 365-8 (2017). (105) Woo, H.I., Kim, S.R., Huh, W., Ko, J.W. & Lee, S.Y. Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects. Drug Des Devel Ther  11, 1135-46 (2017). (106) Lee, N. et al. Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients. Drug Metab Pharmacokinet  34, 387-95 (2019). (107) Tachibana-Iimori, R. et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet  19, 375-80 (2004).', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005;5:352-8.Date 18-05-2020SLCO1B1 521TC: fluvastatine4059NO action is required for this gene-drug interaction.The gene variation increases the plasma concentration of fluvastatin, but there is insufficient evidence to prove an effect on efficacy or side effects.Literature:1. Hirvensalo P et al. Enantiospecific pharmacogenomics of fluvastatin. Clin Pharmacol Ther 2019;106:668-80.2. Mori D et al. Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. Drug Metab Pharmacokinet 2019;34:78-86.3. Xiang Q et al. The association between the SLCO1B1, apolipoprotein E, and CYP2C9 genes and lipid response to fluvastatin: a meta-analysis. Pharmacogenet Genomics 2018;28:261-7.4. Meyer zu Schwabedissen HE et al. Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:1. Choose an alternativeDo not select simvastatin, as this is also affected by the SLCO1B1 gene variation. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms, but are not influenced byCYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced significantly by SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.Patient has NO additional significant risk factors for statin-induced myopathy:1. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Turner RM et al. A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clin Pharmacol Ther 2020 Mar 3 [Epub ahead of print].2. Liu JE et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='myopathy and 1.3% for severe myopathy. When using 40 mg/day, this risk is increased 2.6-fold to 0.39%and 0.17% respectively. The gene variation may lead to reduced simvastatin transport to the liver, which may increase simvastatin plasma concentrations and therefore the risk of side effects.1. Choose an alternativeConsider any additional risk factors for statin-induced myopathy.Atorvastatin is affected less severely by the SLCO1B1 gene variation, but is also affected by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Use of atorvastatin is not recommended for patientswith additional risk factors for statin-induced myopathy.Rosuvastatin and pravastatin are influenced to a lesser extent by the SLCO1B1 gene variation. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.Fluvastatin is not significantly influenced by the SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option:1. Avoid simvastatin doses', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='associated with increased cholesterol synthesis rate. Pharmacogenet Genomics 2008;18:921-6.20. Pasanen MK et al. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007;82:726-33.21. Hermann M et al. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther 2006;79:532-9.22. Thompson JF et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005;5:352-8.Date 18-05-2020NUDT15 IM: azathioprine/mercaptopurine7035Grade ≥ 2 leukopaenia occurs in 42% of these patients with standard immunosuppression therapy. The gene variation increases the concentration of the fully activated metabolite of azathioprine and mercaptopurine.IMMUNOSUPPRESSION:start with 50% of the standard doseAdjustment of the initial dose should be performed based on toxicity (monitoring of the', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'})]

question: What is the effect of phenotype of SLCO1B1 Normal Function on fluvastatin dosage ?
retrieved_docs: [Document(page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,,SLCO1B1 No Result,CYP2C9 normal metabolizer,Pre-test,"This patient is predicted to be a CYP2C9 normal metabolizer. Based on CYP2C9 phenotype there is no reason to adjust the dose of fluvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of myopathy to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Pre-test,"CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005;5:352-8.Date 18-05-2020SLCO1B1 521TC: fluvastatine4059NO action is required for this gene-drug interaction.The gene variation increases the plasma concentration of fluvastatin, but there is insufficient evidence to prove an effect on efficacy or side effects.Literature:1. Hirvensalo P et al. Enantiospecific pharmacogenomics of fluvastatin. Clin Pharmacol Ther 2019;106:668-80.2. Mori D et al. Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. Drug Metab Pharmacokinet 2019;34:78-86.3. Xiang Q et al. The association between the SLCO1B1, apolipoprotein E, and CYP2C9 genes and lipid response to fluvastatin: a meta-analysis. Pharmacogenet Genomics 2018;28:261-7.4. Meyer zu Schwabedissen HE et al. Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 111 NUMBER 5 | May 2022 1013Table 2 Dosing recommendations for statins based on SLCO1B1 phenotype in adults\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nAll statins\nSLCO1B1 increased \nfunctionTypical myopathy risk and \nstatin exposurePrescribe desired starting dose and adjust doses \nbased on disease-  specific guidelinesStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and ancestry should be evaluated \nprior to initiating a statin\nSLCO1B1 normal function Typical myopathy risk and \nstatin exposurePrescribe desired starting dose and adjust doses \nbased on disease-  specific guidelinesStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and ancestry should be evaluated \nprior to initiating a statin\nAtorvastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics  9, 1217-27 (2008). (116) Xiang, Q. et al. The association between the SLCO1B1, apolipoprotein E, and CYP2C9 genes and lipid response to fluvastatin: a meta-analysis. Pharmacogenet Genomics  28, 261-7 (2018). (117) Deng, J.W. et al. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics  18, 424-33 (2008). (118) Xiang, Q. et al. The influence of genetic polymorphisms in drug metabolism enzymes and transporters on the pharmacokinetics of different fluvastatin formulations. Asian J Pharm Sci  15, 264-72 (2020). (119) Hirvensalo, P. et al. Enantiospecific Pharmacogenomics of Fluvastatin. Clin Pharmacol Ther  106, 668-80 (2019). (120) Niemi, M., Pasanen, M.K. & Neuvonen, P.J. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='-Date 14-12-2005CYP2D6 UM: flupentixol1533This is NOT a gene-drug interaction.No studies have been published in which the kinetics and the effects of flupentixol were studied for this phenotype.Literature:-Date 14-12-2005SLCO1B1 521CC: fluvastatine4060NO action is required for this gene-drug interaction.The gene variation increases the plasma concentration of fluvastatin, but there is insufficient evidence to prove an effect on efficacy or side effects.Literature:1. Hirvensalo P et al. Enantiospecific pharmacogenomics of fluvastatin. Clin Pharmacol Ther 2019;106:668-80.2. Mori D et al. Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. Drug Metab Pharmacokinet 2019;34:78-86.3. Xiang Q et al. The association between the SLCO1B1, apolipoprotein E, and CYP2C9 genes and lipid response to fluvastatin: a meta-analysis. Pharmacogenet Genomics 2018;28:261-7.4. Meyer zu Schwabedissen HE et al.', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'})]

question: My patient has a SLCO1B1 Possible Decreased Function. How does this impact pitavastatin dosage ?
retrieved_docs: [Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='and decreased function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins)Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nPitavastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased pitavastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤2 mg as a starting dose and adjust \ndoses of pitavastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for doses \n>1\xa0mg. If dose >2 mg needed for desired efficacy, \nconsider an alternative statin (see Figure\xa01 \nfor recommendations for alternative statins)', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nRosuvastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased rosuvastatin \nexposure as compared \nwith normal function; \ntypical myopathy risk with \ndoses ≤20\xa0mgPrescribe desired starting dose and adjust doses \nof rosuvastatin based on disease-  specific and \npopulation-  specific guidelines. Prescriber should \nbe aware of possible increased risk for myopathy \nespecially for doses >20\xa0mgStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and Asian ancestry should be \nevaluated prior to initiating a statin. The \neffects of drug–  drug interactions may be \nmore pronounced, resulting in a higher risk \nof myopathy\nSLCO1B1 poor function Increased rosuvastatin \nexposure as compared \nwith normal function \nand decreased function;', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pravastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What is the effect of a pgx result of SLCO1B1 Indeterminate on lovastatin dosage ?
retrieved_docs: [Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pravastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient has the following phenotypes -SLCO1B1 Poor Function. How does this impact their atorvastatin dosage?
retrieved_docs: [Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 111 NUMBER 5 | May 2022 1013Table 2 Dosing recommendations for statins based on SLCO1B1 phenotype in adults\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nAll statins\nSLCO1B1 increased \nfunctionTypical myopathy risk and \nstatin exposurePrescribe desired starting dose and adjust doses \nbased on disease-  specific guidelinesStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and ancestry should be evaluated \nprior to initiating a statin\nSLCO1B1 normal function Typical myopathy risk and \nstatin exposurePrescribe desired starting dose and adjust doses \nbased on disease-  specific guidelinesStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and ancestry should be evaluated \nprior to initiating a statin\nAtorvastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >1mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: I take pravastatin for my cholesterol. My doctor recently ordered a genetic test for me and I just got the results. It looks like I have something called SLCO1B1 increased function. What does this mean for my cholesterol and my medication?
retrieved_docs: [Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pravastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: How does SLCO1B1 increased function affect rosuvastatin dosage?
retrieved_docs: [Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nRosuvastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased rosuvastatin \nexposure as compared \nwith normal function; \ntypical myopathy risk with \ndoses ≤20\xa0mgPrescribe desired starting dose and adjust doses \nof rosuvastatin based on disease-  specific and \npopulation-  specific guidelines. Prescriber should \nbe aware of possible increased risk for myopathy \nespecially for doses >20\xa0mgStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and Asian ancestry should be \nevaluated prior to initiating a statin. The \neffects of drug–  drug interactions may be \nmore pronounced, resulting in a higher risk \nof myopathy\nSLCO1B1 poor function Increased rosuvastatin \nexposure as compared \nwith normal function \nand decreased function;', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 increased function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='possible SLCO1B1 decreased \nfunctionPrescribe desired starting dose \nand adjust doses of rosuvastatin \nbased on disease-  specific and \npopulation-  specific guidelines. \nPrescriber should be aware \nof possible increased risk for \nmyopathy especially for doses >20 \nmg. STRONGPrescribe desired starting \ndose and adjust doses of \nrosuvastatin based on disease-  \nspecific and population-  specific \nguidelines. Prescriber should \nbe aware of possible increased \nrisk for myopathy especially for \ndoses >20 mg. MODERATEPrescribe ≤10 mg as a \nstarting dose and adjust \ndoses of rosuvastatin based \non disease-  specific and \npopulation-  specific guidelines. \nIf dose >10 mg needed for \ndesired efficacy, consider \nan alternative statin or \ncombination therapy (i.e., \nrosuvastatin plus nonstatin \nguideline-  directed medical \ntherapy).3 OPTIONAL\nSLCO1B1 poor function Prescribe ≤20 mg as a starting \ndose and adjust doses of \nrosuvastatin based on disease-  \nspecific and population-  specific', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='simvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What are the implications of having SLCO1B1 possible decreased function when taking pravastatin?
retrieved_docs: [Document(page_content='pravastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pravastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pravastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='and dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nPravastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased pravastatin \nexposure as compared \nwith normal function; \ntypical myopathy risk with \ndoses ≤40\xa0mgPrescribe desired starting dose and adjust doses of \npravastatin based on disease-  specific guidelines. \nPrescriber should be aware of possible increased \nrisk for myopathy with pravastatin especially with \ndoses >40\xa0mg per dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathyTable 2  (Continued)\n (Continued)\nCPIC UPDATE', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='function should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nRosuvastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased rosuvastatin \nexposure as compared \nwith normal function; \ntypical myopathy risk with \ndoses ≤20\xa0mgPrescribe desired starting dose and adjust doses \nof rosuvastatin based on disease-  specific and \npopulation-  specific guidelines. Prescriber should \nbe aware of possible increased risk for myopathy \nespecially for doses >20\xa0mgStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and Asian ancestry should be \nevaluated prior to initiating a statin. The \neffects of drug–  drug interactions may be \nmore pronounced, resulting in a higher risk \nof myopathy\nSLCO1B1 poor function Increased rosuvastatin \nexposure as compared \nwith normal function \nand decreased function;', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'})]

question: How does CYP2C9 poor metabolizer status affect fluvastatin prescription?
retrieved_docs: [Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 normal metabolizer,Post-test,"This patient is predicted to be a CYP2C9 normal metabolizer and to have SLCO1B1 poor function. The patient may be at an increased risk of a fluvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose > 40mg is needed for desired efficacy, consider a higher dose (>40mg) if patient is tolerating 40mg per day or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,CYP2C9 poor metabolizer ,Post-test,This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 decreased function. This patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of myopathy to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient s tolerating 40mg per day or an alternative statin or combination therapy. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if CYP2C9 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 intermediate metabolizer,Post-test,This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 poor function. This patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,,SLCO1B1 No Result,CYP2C9 normal metabolizer,Pre-test,"This patient is predicted to be a CYP2C9 normal metabolizer. Based on CYP2C9 phenotype there is no reason to adjust the dose of fluvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient has SLCO1B1 normal function. How does this impact their pitavastatin dosage?
retrieved_docs: [Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'})]

question: What is the effect of SLCO1B1 poor function on atorvastatin dosage?
retrieved_docs: [Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pravastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='of increased atorvastatin response. Int J Mol Sci 2011;12:5815-27.14. Puccetti L et al. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 2010;211:28-9.15. Lee YJ et al. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Int J Clin Pharmacol Ther 2010;48:36-45.16. Voora D et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16.17. Mega JL et al. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 2009;29:1310-5.18. He YJ et al. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta 2009;405:49-52.19. Pasanen MK et al. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals. Eur J Clin Pharmacol 2013;69:1269-74.9. Carr DF et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the Clinical Practice Research Datalink. Clin Pharmacol Ther 2013;94:695-701.10. Francesca Notarangelo M et al. Genetic predisposition to atorvastatin-induced myopathy: a case report. J Clin Pharm Ther 2012;37:604-6.11. Brunham LR et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 2012;12:233-7.12. Santos PC et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol 2012;68:273-9.13. Rodrigues AC et al. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response. Int J Mol Sci', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='myopathy and 1.3% for severe myopathy. When using 40 mg/day, this risk is increased 2.6-fold to 0.39%and 0.17% respectively. The gene variation may lead to reduced simvastatin transport to the liver, which may increase simvastatin plasma concentrations and therefore the risk of side effects.1. Choose an alternativeConsider any additional risk factors for statin-induced myopathy.Atorvastatin is affected less severely by the SLCO1B1 gene variation, but is also affected by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Use of atorvastatin is not recommended for patientswith additional risk factors for statin-induced myopathy.Rosuvastatin and pravastatin are influenced to a lesser extent by the SLCO1B1 gene variation. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.Fluvastatin is not significantly influenced by the SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option:1. Avoid simvastatin doses', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'})]

question: My patient's pgx results just came back. She is a CYP2C9 poor metabolizer and also appears to have SLCO1B1 decreased function, what should I do about her prescription?
retrieved_docs: [Document(page_content='Patients with the CYP2C9 Diplotype *29/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*52  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *31/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *29/*42  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *8/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *28/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *2/*43  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *25/*31  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *24/*29  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'}), Document(page_content='Patients with the CYP2C9 Diplotype *26/*33  display a CYP2C9 Poor Metabolizer phenotype with an activity score of 0.5. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'CYP2C9 Diplotype Phenotype Mapping'})]

question: Is a person with CYP2C9 poor metabolizer and to have SLCO1B1 poor function at increased risk of myopathy if they take fluvastatin?
retrieved_docs: [Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of myopathy to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,,SLCO1B1 No Result,,Pre-test,CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Neither a CYP2C9 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Pre-test,"CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,CYP2C9 poor metabolizer ,Post-test,This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 decreased function. This patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 intermediate metabolizer,Post-test,This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 poor function. This patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What are rosuvastatin dosage implications for ABCG2 poor and SLCO1B1 decreased function?
retrieved_docs: [Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 increased function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 decreased function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 possible decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: Apparently I have something called  ABCG2 decreased function and SLCO1B1 poor function and this might affect my rosuvastatin prescription? Can you help me understand this better?
retrieved_docs: [Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 increased function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 possible decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 decreased function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient has SLCO1B1 decreased fucntion. I did not test her for ABCG2 or CYP2C9. Do I need to make any changes to her rosuvastatin dose? I currently have her on the standard dose. She has not complained of myopathy.
retrieved_docs: [Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 decreased function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nRosuvastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased rosuvastatin \nexposure as compared \nwith normal function; \ntypical myopathy risk with \ndoses ≤20\xa0mgPrescribe desired starting dose and adjust doses \nof rosuvastatin based on disease-  specific and \npopulation-  specific guidelines. Prescriber should \nbe aware of possible increased risk for myopathy \nespecially for doses >20\xa0mgStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and Asian ancestry should be \nevaluated prior to initiating a statin. The \neffects of drug–  drug interactions may be \nmore pronounced, resulting in a higher risk \nof myopathy\nSLCO1B1 poor function Increased rosuvastatin \nexposure as compared \nwith normal function \nand decreased function;', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: How should I adjust the dosage of rosuvastatin for a patient with ABCG2 decreased function and SLCO1B1 normal function?
retrieved_docs: [Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 normal function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1016\nTable 3 Dosing recommendations for rosuvastatin based on ABCG2 phenotype in adults\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nNormal function Typical myopathy risk and rosuvastatin \nexposurePrescribe desired starting dose and \nadjust doses of rosuvastatin based on \ndisease-  specific and population-  specific \nguidelinesStrong The potential for drug–  drug interactions \nand dose limits based on renal and \nhepatic function and Asian ancestry \nshould be evaluated prior to initiating \nrosuvastatin\nDecreased \nfunctionIncreased rosuvastatin exposure as \ncompared with normal function; unknown \nrisk for myopathy; increased lipid-  lowering \neffectsPrescribe desired starting dose and \nadjust doses of rosuvastatin based \non disease-  specific guidelines and \npopulation-  specific guidelinesModerate The potential for drug–  drug interactions \nand dose limits based on renal and', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='possible SLCO1B1 decreased \nfunctionPrescribe desired starting dose \nand adjust doses of rosuvastatin \nbased on disease-  specific and \npopulation-  specific guidelines. \nPrescriber should be aware \nof possible increased risk for \nmyopathy especially for doses >20 \nmg. STRONGPrescribe desired starting \ndose and adjust doses of \nrosuvastatin based on disease-  \nspecific and population-  specific \nguidelines. Prescriber should \nbe aware of possible increased \nrisk for myopathy especially for \ndoses >20 mg. MODERATEPrescribe ≤10 mg as a \nstarting dose and adjust \ndoses of rosuvastatin based \non disease-  specific and \npopulation-  specific guidelines. \nIf dose >10 mg needed for \ndesired efficacy, consider \nan alternative statin or \ncombination therapy (i.e., \nrosuvastatin plus nonstatin \nguideline-  directed medical \ntherapy).3 OPTIONAL\nSLCO1B1 poor function Prescribe ≤20 mg as a starting \ndose and adjust doses of \nrosuvastatin based on disease-  \nspecific and population-  specific', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='starting dose and adjust \ndoses of rosuvastatin based \non disease-  specific and \npopulation-  specific guidelines. \nIf dose >20 mg needed for \ndesired efficacy, consider \nan alternative statin or \ncombination therapy (i.e., \nrosuvastatin plus nonstatin \nguideline-  directed medical \ntherapy).3 OPTIONAL\nSLCO1B1 normal function Prescribe desired starting dose \nand adjust doses of rosuvastatin \nbased on disease-  specific and \npopulation-  specific guidelines. \nSTRONGPrescribe desired starting \ndose and adjust doses of \nrosuvastatin based on disease-  \nspecific and population-  specific \nguidelines. MODERATEPrescribe ≤20 mg as a \nstarting dose and adjust \ndoses of rosuvastatin based \non disease-  specific and \npopulation-  specific guidelines. \nIf dose >20 mg needed for \ndesired efficacy, consider \nan alternative statin or \ncombination therapy (i.e., \nrosuvastatin plus nonstatin \nguideline-  directed medical \ntherapy).3 OPTIONAL\nSLCO1B1 decreased function or \npossible SLCO1B1 decreased', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient's genetic test shows both CYP2C9 normal metabolizer and SLCO1B1 poor function. What does this mean for their fluvastatin prescription?
retrieved_docs: [Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,,SLCO1B1 No Result,CYP2C9 normal metabolizer,Pre-test,"This patient is predicted to be a CYP2C9 normal metabolizer. Based on CYP2C9 phenotype there is no reason to adjust the dose of fluvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of myopathy to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 normal metabolizer,Post-test,"This patient is predicted to be a CYP2C9 normal metabolizer and to have SLCO1B1 poor function. The patient may be at an increased risk of a fluvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose > 40mg is needed for desired efficacy, consider a higher dose (>40mg) if patient is tolerating 40mg per day or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,CYP2C9 poor metabolizer ,Post-test,This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 decreased function. This patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 intermediate metabolizer,Post-test,This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 poor function. This patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Pre-test,"CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient s tolerating 40mg per day or an alternative statin or combination therapy. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if CYP2C9 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What drug should I order for a phenotype of SLCO1B1 Possible Decreased Function and ABCG2 Poor Function?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *2/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*25 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*12 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*20 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*5 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*15 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*15 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *3/*5 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *10/*15 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*10 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: What are the guidelines for SLCO1B1 Poor Function and ABCG2 Decreased Function ?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *2/*5 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*20 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*20 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *3/*5 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*47 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*15 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *4/*5 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*15 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *12/*15 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My patient has SLCO1B1 Poor Function and ABCG2 Normal Function. What are the drug dosage guidelines?
retrieved_docs: [Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have SLCO1B1 normal function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 normal function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 normal function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*9 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My patient's Pgx results indicate SLCO1B1 Increased Function and ABCG2 Poor Function. What should I know about appropriate drug dosage?
retrieved_docs: [Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have SLCO1B1 normal function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What is myotpathy risk for a patient with SLCO1B1 Increased Function and ABCG2 Poor Function ?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *2/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*5 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *8/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*48 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *28/*48 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*8 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*9 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *3/*5 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*23 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: How should I adjust fluvastation dose for my patient with CYP2C9 poor metabolizer? They were not tested on SLCO1B1.
retrieved_docs: [Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,,SLCO1B1 No Result,CYP2C9 normal metabolizer,Pre-test,"This patient is predicted to be a CYP2C9 normal metabolizer. Based on CYP2C9 phenotype there is no reason to adjust the dose of fluvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient s tolerating 40mg per day or an alternative statin or combination therapy. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if CYP2C9 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 111 NUMBER 5 | May 2022 1017Table 4 Dosing recommendations for fluvastatin based on CYP2C9 phenotype in adults\nPhenotype Implication Dosing recommendationsClassification of \nrecommendationsaConsiderations\nCYP2C9 normal metabolizer Normal exposure Prescribe desired starting dose and \nadjust doses of fluvastatin based on \ndisease-  specific guidelinesStrong The potential for drug–  drug \ninteractions and dose limits \nbased on renal and hepatic \nfunction should be evaluated prior \nto initiating a statin\nCYP2C9 intermediate metabolizer AS \nof 1 and 1.5Increased fluvastatin exposure as \ncompared with normal metabolizer, \nwhich may translate to increased \nmyopathy riskPrescribe ≤40\xa0mg per day as a \nstarting dose and adjust doses of \nfluvastatin based on disease-  specific \nguidelines. If dose >40\xa0mg needed \nfor desired efficacy, consider an \nalternative statin or combination \ntherapy (i.e., fluvastatin plus nonstatin', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 intermediate metabolizer,Post-test,This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 poor function. Thise patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: I ordered a pgx test for my patient before prescribing fluvastatin. The SLCO1B1 result was indeterminate and the CYP2C9 gene shows intermediate metabolizer. Can I prescrible recommended dosage or should I adjust dosage based on their pgx result?
retrieved_docs: [Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of myopathy to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,,SLCO1B1 No Result,CYP2C9 normal metabolizer,Pre-test,"This patient is predicted to be a CYP2C9 normal metabolizer. Based on CYP2C9 phenotype there is no reason to adjust the dose of fluvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score n/a,,,,SLCO1B1 No Result,CYP2C9 Indeterminate,Pre-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because an SLCO1B1 genotype does not appear to have been ordered for this patient and CYP2C9 phenotype could not be assigned based on genotyping performed, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,,SLCO1B1 No Result,,Pre-test,CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Neither a CYP2C9 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Pre-test,"CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient s tolerating 40mg per day or an alternative statin or combination therapy. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if CYP2C9 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient has SLCO1B1 decreased fucntion. I did not test her for ABCG2 or CYP2C9. Do I need to make any changes to her fluvastatin dose? I currently have her on the standard dose. She has not complained of myopathy.
retrieved_docs: [Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,,SLCO1B1 No Result,,Pre-test,CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Neither a CYP2C9 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient is CYP2C9 normal metabolizer and SLCO1B1 poor function. Does this affect her statin dosing?
retrieved_docs: [Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,,SLCO1B1 No Result,CYP2C9 normal metabolizer,Pre-test,"This patient is predicted to be a CYP2C9 normal metabolizer. Based on CYP2C9 phenotype there is no reason to adjust the dose of fluvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of myopathy to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >1mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 intermediate metabolizer,Post-test,This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 poor function. Thise patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient is CYP2C9 poor metabolizer and SLCO1B1 poor function. Does this affect her statin dosing?
retrieved_docs: [Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,,SLCO1B1 No Result,CYP2C9 normal metabolizer,Pre-test,"This patient is predicted to be a CYP2C9 normal metabolizer. Based on CYP2C9 phenotype there is no reason to adjust the dose of fluvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >1mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient s tolerating 40mg per day or an alternative statin or combination therapy. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if CYP2C9 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 intermediate metabolizer,Post-test,This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 poor function. Thise patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient takes fluvastatin and complained of muscle pains. I orderded a pgx test targeting statins. His results show CYP2C9 intermediate metabolizer and SLCO1B1 possible decreased function. What does this mean for his lescol.
retrieved_docs: [Document(page_content='fluvastatin,CYP2C9 Activity Score 1.0,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,,SLCO1B1 No Result,CYP2C9 intermediate metabolizer,Post-test,"CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of myopathy to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.5,,,,SLCO1B1 No Result,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,,SLCO1B1 No Result,,Pre-test,CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Neither a CYP2C9 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score No result on file,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Pre-test,"CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 intermediate metabolizer,Post-test,"This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,CYP2C9 poor metabolizer ,Post-test,"This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 2.0,,,,SLCO1B1 No Result,CYP2C9 normal metabolizer,Pre-test,"This patient is predicted to be a CYP2C9 normal metabolizer. Based on CYP2C9 phenotype there is no reason to adjust the dose of fluvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 0.0,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,CYP2C9 poor metabolizer ,Post-test,This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 decreased function. This patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='fluvastatin,CYP2C9 Activity Score 1.5,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,CYP2C9 intermediate metabolizer,Post-test,This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 poor function. This patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient's pgx result shows poor function for both ABCG2 and SLCO1B1. How does this affect her statin dosing?
retrieved_docs: [Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >1mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient's pgx result shows ABCG2 poor function and SLCO1B1 normal function. How does this affect her statin dosing?
retrieved_docs: [Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have SLCO1B1 normal function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 normal function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >1mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: Does ABCG2 normal function and SLCO1B1 increased function impact rosuvastatin prescription?
retrieved_docs: [Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,,SLCO1B1 No Result,,Pre-test,"This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have SLCO1B1 normal function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 possible decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 reference (G),ABCG2 Normal Function,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have ABCG2 normal function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have ABCG2 poor function and SLCO1B1 increased function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: What are the CPIC guidelines for a phenotype of SLCO1B1 Poor Function?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *5/*15 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*15 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*9 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*31 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*5 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *5/*48 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *15/*47 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *15/*31 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*48 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *31/*49 display a SLC01B1 Poor Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: My patient has SLCO1B1 decreased function . What statin should I prescribe?
retrieved_docs: [Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pravastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pravastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='and decreased function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins)Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nPitavastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased pitavastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤2 mg as a starting dose and adjust \ndoses of pitavastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for doses \n>1\xa0mg. If dose >2 mg needed for desired efficacy, \nconsider an alternative statin (see Figure\xa01 \nfor recommendations for alternative statins)', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 111 NUMBER 5 | May 2022 1013Table 2 Dosing recommendations for statins based on SLCO1B1 phenotype in adults\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nAll statins\nSLCO1B1 increased \nfunctionTypical myopathy risk and \nstatin exposurePrescribe desired starting dose and adjust doses \nbased on disease-  specific guidelinesStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and ancestry should be evaluated \nprior to initiating a statin\nSLCO1B1 normal function Typical myopathy risk and \nstatin exposurePrescribe desired starting dose and adjust doses \nbased on disease-  specific guidelinesStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and ancestry should be evaluated \nprior to initiating a statin\nAtorvastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'})]

question: What are the associated drugs for a phenotype of SLCO1B1 Decreased Function?
retrieved_docs: [Document(page_content='CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 111 NUMBER 5 | May 2022 1009allele have an SLCO1B1 decreased function phenotype and \nindividuals with two no function alleles ( e.g., SLCO1B1*5/*5 ) \nhave an SLCO1B1 poor function phenotype.\nThe most common and well- studied variant in SLCO1B1 is \nc.521T>C (rs4149056), and it can be genotyped alone (e.g., poly -\nmerase chain reaction–  based single SNV assay) or multiplexed \non a variety of array-  based platforms. All SLCO1B1 genetic tests \nshould interrogate c.521T>C; however, while other less common \nvariants in this gene may have limited evidence to guide action, \nthey may also be important (SLCO1B1 Allele Definition T able \nand SLCO1B1 Allele Functionality T able6,7).ABCG2.  Unlike SLCO1B1  and CYP2C9 , there is no star allele \nnomenclature to represent ABCG2  variants at this time. \nAssignment of the predicted ABCG2 phenotype is summarized \nin Table\xa0 1. An individual carrying one normal function allele plus', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*5 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*9 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*15 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*49 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*47 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *9/*14 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *26/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*46 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *30/*49 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: What does it mean to have SLCO1B1 Increased function?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *1/*23 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*5 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*15 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*9 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*31 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *25/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *23/*25 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *3/*5 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

question: What are statin dosage guidelines for SLCO1B1 Decreased Function?
retrieved_docs: [Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 111 NUMBER 5 | May 2022 1013Table 2 Dosing recommendations for statins based on SLCO1B1 phenotype in adults\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nAll statins\nSLCO1B1 increased \nfunctionTypical myopathy risk and \nstatin exposurePrescribe desired starting dose and adjust doses \nbased on disease-  specific guidelinesStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and ancestry should be evaluated \nprior to initiating a statin\nSLCO1B1 normal function Typical myopathy risk and \nstatin exposurePrescribe desired starting dose and adjust doses \nbased on disease-  specific guidelinesStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and ancestry should be evaluated \nprior to initiating a statin\nAtorvastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 111 NUMBER 5 | May 2022 1015Phenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nSLCO1B1 poor function Increased pravastatin \nstatin exposure as \ncompared with normal \nand decreased function; \ntypical myopathy risk with \ndoses ≤40\xa0mgPrescribe ≤40 mg as a starting dose and adjust \ndoses of pravastatin based on disease-  specific \nguidelines. If patient is tolerating 40-  mg dose \nbut higher potency is needed, a higher dose \n(>40 mg) or an alternative statin (see Figure\xa01 \nfor recommendations for alternative statins) \nor combination therapy (i.e., pravastatin plus \nnonstatin guideline-  directed medical therapy)3 \ncould be considered. Prescriber should be aware of \npossible increased risk for myopathy especially with \npravastatin doses >40\xa0mgModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='possible SLCO1B1 decreased \nfunctionPrescribe desired starting dose \nand adjust doses of rosuvastatin \nbased on disease-  specific and \npopulation-  specific guidelines. \nPrescriber should be aware \nof possible increased risk for \nmyopathy especially for doses >20 \nmg. STRONGPrescribe desired starting \ndose and adjust doses of \nrosuvastatin based on disease-  \nspecific and population-  specific \nguidelines. Prescriber should \nbe aware of possible increased \nrisk for myopathy especially for \ndoses >20 mg. MODERATEPrescribe ≤10 mg as a \nstarting dose and adjust \ndoses of rosuvastatin based \non disease-  specific and \npopulation-  specific guidelines. \nIf dose >10 mg needed for \ndesired efficacy, consider \nan alternative statin or \ncombination therapy (i.e., \nrosuvastatin plus nonstatin \nguideline-  directed medical \ntherapy).3 OPTIONAL\nSLCO1B1 poor function Prescribe ≤20 mg as a starting \ndose and adjust doses of \nrosuvastatin based on disease-  \nspecific and population-  specific', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='and decreased function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins)Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nPitavastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased pitavastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤2 mg as a starting dose and adjust \ndoses of pitavastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for doses \n>1\xa0mg. If dose >2 mg needed for desired efficacy, \nconsider an alternative statin (see Figure\xa01 \nfor recommendations for alternative statins)', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='10 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  STRENGTH OF DOSING RECOMMENDATIONS CPIC’s dosing recommendations are based on weighing the evidence from a combination of preclinical functional and clinical data (Supplemental Tables S1-S3) as well as on some existing disease-specific consensus guidelines (30). Some of the factors that are considered in evaluating the evidence supporting dosage recommendations include: in vivo clinical outcome data for statins, in vivo pharmacokinetic and pharmacodynamic data for statins, in vitro enzyme/transporter activity of expressed wild-type or variant-containing gene, in vitro enzyme activity from tissues isolated from individuals of known genotypes, in vivo pre-clinical pharmacokinetic and pharmacodynamic studies, and in vitro studies of protein stability.   Overall, the therapeutic recommendations are simplified to allow rapid interpretation by clinicians. CPIC uses a slight modification of a transparent and simple', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='function should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nRosuvastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased rosuvastatin \nexposure as compared \nwith normal function; \ntypical myopathy risk with \ndoses ≤20\xa0mgPrescribe desired starting dose and adjust doses \nof rosuvastatin based on disease-  specific and \npopulation-  specific guidelines. Prescriber should \nbe aware of possible increased risk for myopathy \nespecially for doses >20\xa0mgStrong The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction and Asian ancestry should be \nevaluated prior to initiating a statin. The \neffects of drug–  drug interactions may be \nmore pronounced, resulting in a higher risk \nof myopathy\nSLCO1B1 poor function Increased rosuvastatin \nexposure as compared \nwith normal function \nand decreased function;', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My pharma genetic test shows that I have SLCO1B1 increased function. Does this impact any medications I take?
retrieved_docs: [Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,Post-test,"This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='de novo variants are often not tested for within currently available genotyping tests, if discovered, it may be unclear how to act upon such results. Yet, rare exonic variants in SLCO1B1 have been shown to have clinical impact (e.g., methotrexate clearance) (66). Therefore, altered drug kinetics and increased risk for severe drug toxicity may still occur in the absence of a c.521 C allele, and a c.521TT genotype at rs4149056 does not necessarily imply the absence of other potentially function-altering variant(s) in SLCO1B1. Allele and variant function are available on PharmVar.org as well as CPIC’s SLCO1B1Allele Functionality Table (67, 68).  RESOURCES TO INCORPORATE PHARMACOGENETICS INTO AN EHR WITH CDS  Clinical decision support (CDS) tools integrated within electronic health records (EHRs) can help guide clinical pharmacogenetics at the point of care (69-73).  See https://cpicpgx.org/guidelines/cpic-guideline-for-statins/ for resources to support the adoption of CPIC guidelines', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='test information by providers and is available at http://www.ncbi.nlm.nih.gov/gtr/.   LINKING GENETIC VARIABILITY TO VARIABILITY IN DRUG-RELATED PHENOTYPES  SLCO1B1. Both SLCO1B1 decreased and poor function phenotypes are associated with increased exposure for most statins, with greater effects of poor function phenotypes.  Effects on exposure also vary by statin type (Figure S1). Therefore, the risk of SAMS varies based on statin type and statin dose. For simvastatin, the evidence linking SAMS to SLCO1B1 rs4149056 (c.521T>C) is of high quality, and this association has been reproduced in retrospective studies of randomized trials and clinical practice-based cohorts (Table S1). This variant is present in several SLCO1B1 star alleles including the relatively common SLCO1B1*5 and *15 alleles. Although the association of rs4149056 with myopathy varies by statin, there is evidence supporting the role of SLCO1B1 variants in the systemic clearance of all statins (3) (Table S1).  Pasanen et', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 111 NUMBER 5 | May 2022 1009allele have an SLCO1B1 decreased function phenotype and \nindividuals with two no function alleles ( e.g., SLCO1B1*5/*5 ) \nhave an SLCO1B1 poor function phenotype.\nThe most common and well- studied variant in SLCO1B1 is \nc.521T>C (rs4149056), and it can be genotyped alone (e.g., poly -\nmerase chain reaction–  based single SNV assay) or multiplexed \non a variety of array-  based platforms. All SLCO1B1 genetic tests \nshould interrogate c.521T>C; however, while other less common \nvariants in this gene may have limited evidence to guide action, \nthey may also be important (SLCO1B1 Allele Definition T able \nand SLCO1B1 Allele Functionality T able6,7).ABCG2.  Unlike SLCO1B1  and CYP2C9 , there is no star allele \nnomenclature to represent ABCG2  variants at this time. \nAssignment of the predicted ABCG2 phenotype is summarized \nin Table\xa0 1. An individual carrying one normal function allele plus', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Voora D et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16.16. Pasanen MK et al. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenet Genomics 2008;18:921-6.17. SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy -- a genomewide study. N Engl J Med 2008;359:789-99.18. Pasanen MK et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006;16:873-9.19. Ramsey LB et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther 2014;96:423-8.20. SmPC Zocor.Date 18-05-2020SLCO1B1 521TC: simvastatine4055When using simvastatin 80 mg/day, the risk of myopathy is increased 5-fold to 3% for moderately severe to severe myopathy and 1.3% for severe myopathy. When', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*1,SLCO1B1 *1/*14,SLCO1B1 *1/*20,SLCO1B1 *1/*37,SLCO1B1 *14/*37,SLCO1B1 *20/*37,SLCO1B1 *37/*37",SLCO1B1 Normal Function,,Post-test,"This patient is predicted to have SLCO1B1 normal function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Pre-test,"This patient is predicted to have SLCO1B1 decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*9 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Cardiol 2009;54:1609-16.16. Pasanen MK et al. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenet Genomics 2008;18:921-6.17. SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy -- a genomewide study. N Engl J Med 2008;359:789-99.18. Pasanen MK et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006;16:873-9.19. Ramsey LB et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther 2014;96:423-8.20. SmPC Zocor.Date 18-05-2020CYP2C9 *1/*2: siponimod7160NO action is required for this gene-drug interaction.The genetic variation can slightly increase the exposure to siponimod. However, the effect is too small to expect any impact on efficacy or adverse effects.Literature:1. Gardin A et al. Siponimod', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'})]

question: My patient takes pravastatin for their high cholesterol and is complaining of muscle pain after they started taking their medication. Genetic test results show that they have SLCO1B1 decreased function. How should I adjust dosage?
retrieved_docs: [Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pravastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:1. Choose an alternativeDo not select simvastatin, as this is also affected by the SLCO1B1 gene variation. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms, but are not influenced byCYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced significantly by SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.Patient has NO additional significant risk factors for statin-induced myopathy:1. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Turner RM et al. A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clin Pharmacol Ther 2020 Mar 3 [Epub ahead of print].2. Liu JE et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='is not an option:1. Avoid simvastatin doses exceeding 40 mg/day2. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Xiang Q et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J 2018;18:721-9.2. Wu X et al. Associations of the SLCO1B1 polymorphisms with hepatic function, baseline lipid levels, and lipid-lowering response to simvastatin in patients with hyperlipidemia. Clin Appl Thromb Hemost2018;24:240S-247S.3. Kitzmiller JP et al. Candidate-gene study of functional polymorphisms in SLCO1B1 and CYP3A4/5 and the cholesterol-lowering response to simvastatin. Clin Transl Sci 2017;10:172-7.4. Jiang J et al. Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: a meta-analysis. Springerplus 2016;5:1368.5. Hou Q et al. Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient takes Simvastatin but is complaining of myopathy. Can you tell me the genes and  function of those genes that could potentially cause myopathy so that I can order an appropriate pgx test for my patient?
retrieved_docs: [Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='RISK FACTORS for statin-induced myopathy:1. Choose an alternativeRosuvastatin and pravastatin are influenced to a similar extent by the SLCO1B1 gene variation, but are not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem.Fluvastatin is not influenced significantly by the SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.Patient has NO additional significant risk factors for statin-induced myopathy:1. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Turner RM et al. A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clin Pharmacol Ther 2020 Mar 3 [Epub ahead of print].2. Liu JE et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur J Clin Pharmacol', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='(as a function of statin type and dose, comedications, and the pathophysiological or genetic setting). \nIf the genotype is not known early, the RNPGx considers that a polymo rphism test is potentially \nuseful  in the event of muscle toxicity in patients treated with statins, in order to rule out or confirm a \ngenetic cause [12, 13].  \n \nConclusion s \n \nProgress achieved in recent years in the field of genetics has broadened our knowledge of the \nmolecular mechanisms implicated in the therapeutic response or the toxicity of drugs widely used \nfor cardiovascular diseases. The level of evidence  for pharmacoge netic tools available today is \nsufficient for clinical applications designed to predict and anticipate VKA resistance or hemorrhagic', metadata={'link': 'http://dx.doi.org/doi:10.1016/j.therap.2016.09.017', 'source': 'Fabien LamoureuxThomas Duflotthe French Network of Pharmacogenetics (RNPGX), Pharmacogenetics in cardiovascular diseases (2017), http://dx.doi.org/10.1016/j.therap.2016.09.017'}), Document(page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 33  (20) Postmus, I. et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun  5, 5068 (2014). (21) Keskitalo, J.E., Zolk, O., Fromm, M.F., Kurkinen, K.J., Neuvonen, P.J. & Niemi, M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther  86, 197-203 (2009). (22) DeGorter, M.K. et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet  6, 400-8 (2013). (23) Bai, X. et al. Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites. Acta Pharmacol Sin  40, 492-9 (2019). (24) Chu, A.Y. et al. Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein-Related Measures. Circ', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 45  (237) Shin, J., Pauly, D.F., Pacanowski, M.A., Langaee, T., Frye, R.F. & Johnson, J.A. Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. Pharmacotherapy  31, 942-50 (2011).', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='Page 14 of 28Accepted Manuscript\n14 \n - a posterori  genotyping: a SLCO1B1  test may be indicated after initiating treatment to \nexplain muscle symptoms in a patient taki ng statins (myalgia and/or muscle weakness with \nor without elevation of creatinine phosphokinase levels).  \n \n \nResults  (drug selection, contraindications,  dosage)  \n \nStatin exposure (especially with simvastatin) and risk of myopathy are always higher in p atients \nwho are carriers of one or more SLCO1B1  alleles associated with OATP1B1  deficiency . This risk \nof myopathy is correlated with administered dose, the degree of the OATP1B1 activity deficit, and \ntreatment combination with OATP1B1 and/or CYP3A4/5 isofo rm inhibitors (e.g. ciclosporin). The \nmain risk factors for statin -related myotoxicity are: genetic ( e.g. SLCO1B1, CYP3A4/5,…), \npathophysiological (kidney failure, history of myopathy, diabetes mellitus, very young or very old', metadata={'link': 'http://dx.doi.org/doi:10.1016/j.therap.2016.09.017', 'source': 'Fabien LamoureuxThomas Duflotthe French Network of Pharmacogenetics (RNPGX), Pharmacogenetics in cardiovascular diseases (2017), http://dx.doi.org/10.1016/j.therap.2016.09.017'}), Document(page_content='rosuvastatin,,,ABCG2 No Result,,SLCO1B1 No Result,,Pre-test,ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='29 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  TABLE S5.  EVIDENCE LINKING CYP3A4/5 GENOTYPE WITH STATIN PHENOTYPE  Type of experimental model (in vitro, in vivo preclinical, or clinical) Major Findings References  Level of Evidence Clinical CYP3A5*3/*3 genotype (6986A>G) is associated with simvastatin-induced muscle symptoms. Shek, et al. (2017) (134) Liu, et al. (2017) (91)  Weak Clinical  CYP3A5*3/*3 genotype (6986A>G) is more frequent in statin-intolerant cases. Shek, et al. (2018) (162) Weak Clinical CYP3A5*3/*3 genotype (6986A>G) is associated with simvastatin-induced liver symptoms. Shek, et al. (2017) (134) Weak Clinical When simvastatin-intolerant patients were switched to rosuvastatin, serious side effect were not observed and many of them carry CYP3A5*3/*3. Shek, et al. (2018) (162) Weak Clinical  CYP3A4 rs2740574 (G>A) G allele is associated with smaller risk of a dose decrease or switch to another drug during simvastatin and atorvastatin', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 43  (201) Ying, S., Sun, Y.M., Liu, X.M., An, C.Y. & Gao, Y.Y. Effect of ScrF I polymorphism in the 2nd intron of the HMGCR gene on lipid-lowering response to simvastatin in Chinese diabetic patients. Biochem Biophys Res Commun  363, 395-8 (2007). (202) Medina, M.W., Gao, F., Ruan, W., Rotter, J.I. & Krauss, R.M. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation  118, 355-62 (2008). (203) Chasman, D.I., Posada, D., Subrahmanyan, L., Cook, N.R., Stanton, V.P., Jr. & Ridker, P.M. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA : the journal of the American Medical Association  291, 2821-7 (2004). (204) Polisecki, E. et al. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'})]

question: My pgx test result shows that I have possible decreased function in the gene slco1b1, what does this mean for my statin medication?
retrieved_docs: [Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'})]

question: My patient takes pravastatin, can poor function SLCO1B1 phenotype cause myopathy?
retrieved_docs: [Document(page_content='pravastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pravastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pravastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >1mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 variant (T)/rs2231142 variant (T),ABCG2 Poor Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:1. Choose an alternativeDo not select simvastatin, as this is also affected by the SLCO1B1 gene variation. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms, but are not influenced byCYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced significantly by SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.Patient has NO additional significant risk factors for statin-induced myopathy:1. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Turner RM et al. A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clin Pharmacol Ther 2020 Mar 3 [Epub ahead of print].2. Liu JE et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='Page 14 of 28Accepted Manuscript\n14 \n - a posterori  genotyping: a SLCO1B1  test may be indicated after initiating treatment to \nexplain muscle symptoms in a patient taki ng statins (myalgia and/or muscle weakness with \nor without elevation of creatinine phosphokinase levels).  \n \n \nResults  (drug selection, contraindications,  dosage)  \n \nStatin exposure (especially with simvastatin) and risk of myopathy are always higher in p atients \nwho are carriers of one or more SLCO1B1  alleles associated with OATP1B1  deficiency . This risk \nof myopathy is correlated with administered dose, the degree of the OATP1B1 activity deficit, and \ntreatment combination with OATP1B1 and/or CYP3A4/5 isofo rm inhibitors (e.g. ciclosporin). The \nmain risk factors for statin -related myotoxicity are: genetic ( e.g. SLCO1B1, CYP3A4/5,…), \npathophysiological (kidney failure, history of myopathy, diabetes mellitus, very young or very old', metadata={'link': 'http://dx.doi.org/doi:10.1016/j.therap.2016.09.017', 'source': 'Fabien LamoureuxThomas Duflotthe French Network of Pharmacogenetics (RNPGX), Pharmacogenetics in cardiovascular diseases (2017), http://dx.doi.org/10.1016/j.therap.2016.09.017'}), Document(page_content='Voora D et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16.16. Pasanen MK et al. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenet Genomics 2008;18:921-6.17. SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy -- a genomewide study. N Engl J Med 2008;359:789-99.18. Pasanen MK et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006;16:873-9.19. Ramsey LB et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther 2014;96:423-8.20. SmPC Zocor.Date 18-05-2020SLCO1B1 521TC: simvastatine4055When using simvastatin 80 mg/day, the risk of myopathy is increased 5-fold to 3% for moderately severe to severe myopathy and 1.3% for severe myopathy. When', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='Clinical SLCO1B1*17 is associated with an increased risk of simvastatin-induced myopathy. Chan, et al. (2019) (139)   Weak Clinical SLCO1B1 rs4149056 C (c.521T>C) polymorphism markedly affects the pharmacokinetics of active simvastatin acid, but has no significant effect on parent simvastatin. Pasanen, et al. (2006) (4) Zhou, et al. (2013) (140) Tsamandouras, et al. (2014) (141) High', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'})]

question: My patient takes simvastatin, what SLCO1B1 phenotype  can cause myopathy?
retrieved_docs: [Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:1. Choose an alternativeDo not select simvastatin, as this is also affected by the SLCO1B1 gene variation. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms, but are not influenced byCYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced significantly by SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.Patient has NO additional significant risk factors for statin-induced myopathy:1. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Turner RM et al. A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clin Pharmacol Ther 2020 Mar 3 [Epub ahead of print].2. Liu JE et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 37  (94) Ramakumari, N., Indumathi, B., Katkam, S.K. & Kutala, V.K. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects. Indian Heart J  70 Suppl 3, S120-S5 (2018). (95) Mori, D. et al. Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. Drug Metab Pharmacokinet  34, 78-86 (2019). (96) Linskey, D.W. et al. Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms. Pharmacogenet Genomics  30, 208-11 (2020). (97) Turner, R.M. et al. A Genome-wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites. Clin Pharmacol Ther  108, 287-97 (2020). (98) Fukunaga, K., Nakagawa, H., Ishikawa, T., Kubo, M. & Mushiroda, T. ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population.', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='Clinical SLCO1B1*17 is associated with an increased risk of simvastatin-induced myopathy. Chan, et al. (2019) (139)   Weak Clinical SLCO1B1 rs4149056 C (c.521T>C) polymorphism markedly affects the pharmacokinetics of active simvastatin acid, but has no significant effect on parent simvastatin. Pasanen, et al. (2006) (4) Zhou, et al. (2013) (140) Tsamandouras, et al. (2014) (141) High', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals. Eur J Clin Pharmacol 2013;69:1269-74.9. Carr DF et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the Clinical Practice Research Datalink. Clin Pharmacol Ther 2013;94:695-701.10. Francesca Notarangelo M et al. Genetic predisposition to atorvastatin-induced myopathy: a case report. J Clin Pharm Ther 2012;37:604-6.11. Brunham LR et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 2012;12:233-7.12. Santos PC et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol 2012;68:273-9.13. Rodrigues AC et al. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response. Int J Mol Sci', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='Page 14 of 28Accepted Manuscript\n14 \n - a posterori  genotyping: a SLCO1B1  test may be indicated after initiating treatment to \nexplain muscle symptoms in a patient taki ng statins (myalgia and/or muscle weakness with \nor without elevation of creatinine phosphokinase levels).  \n \n \nResults  (drug selection, contraindications,  dosage)  \n \nStatin exposure (especially with simvastatin) and risk of myopathy are always higher in p atients \nwho are carriers of one or more SLCO1B1  alleles associated with OATP1B1  deficiency . This risk \nof myopathy is correlated with administered dose, the degree of the OATP1B1 activity deficit, and \ntreatment combination with OATP1B1 and/or CYP3A4/5 isofo rm inhibitors (e.g. ciclosporin). The \nmain risk factors for statin -related myotoxicity are: genetic ( e.g. SLCO1B1, CYP3A4/5,…), \npathophysiological (kidney failure, history of myopathy, diabetes mellitus, very young or very old', metadata={'link': 'http://dx.doi.org/doi:10.1016/j.therap.2016.09.017', 'source': 'Fabien LamoureuxThomas Duflotthe French Network of Pharmacogenetics (RNPGX), Pharmacogenetics in cardiovascular diseases (2017), http://dx.doi.org/10.1016/j.therap.2016.09.017'}), Document(page_content='is not an option:1. Avoid simvastatin doses exceeding 40 mg/day2. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Xiang Q et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J 2018;18:721-9.2. Wu X et al. Associations of the SLCO1B1 polymorphisms with hepatic function, baseline lipid levels, and lipid-lowering response to simvastatin in patients with hyperlipidemia. Clin Appl Thromb Hemost2018;24:240S-247S.3. Kitzmiller JP et al. Candidate-gene study of functional polymorphisms in SLCO1B1 and CYP3A4/5 and the cholesterol-lowering response to simvastatin. Clin Transl Sci 2017;10:172-7.4. Jiang J et al. Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: a meta-analysis. Springerplus 2016;5:1368.5. Hou Q et al. Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 45  (237) Shin, J., Pauly, D.F., Pacanowski, M.A., Langaee, T., Frye, R.F. & Johnson, J.A. Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. Pharmacotherapy  31, 942-50 (2011).', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='N.S., Neely, D., Avery, P., Brown, C., Daly, A.K. & Kamali, F. Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study. Clin Pharmacol Ther  104, 178-87 (2018). (136) Flores-Unzueta, S. et al. Simvastatin-related myopathy in shift workers: a report of two cases. Drug Metab Pers Ther  33, 153-6 (2018). (137) Carr, D.F. et al. Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink. Clin Pharmacol Ther  106, 1353-61 (2019). (138) S, C.T. et al. A pilot study on the association between SLCO1B1 RS4363657 polymorphism and muscle adverse events in adults with newly diagnosed dyslipidaemia who were prescribed a statin: the Malaysian primary health care cohort. Biomarkers  24, 659-65 (2019). (139) Chan, J.C.M., Ng, M.H., Wong, R.S.M. & Tomlinson, B. A case of simvastatin-induced myopathy with SLCO1B1 genetic predisposition and co-ingestion of linagliptin and', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'})]

question: What phenotype function causes increased myopathy risk for lovastatin?
retrieved_docs: [Document(page_content='rosuvastatin levels (AUC and Cmax) may be doubled in individuals with poor function phenotypes (21). Based on the observed increase in exposure, the risk for myopathy would also be expected to be increased (22). Nonetheless, there is only a single study directly assessing myopathy due to rosuvastatin use in individuals with decreased or poor function phenotypes which did not show any significant effect on myopathy (23). However, for efficacy, the JUPITER Trial showed an increase in lipid lowering effects of rosuvastatin in individuals with decreased and poor function phenotypes (24).  Dosing based on genotype for rosuvastatin must necessarily include other considerations such as liver or renal function and ancestry (Table 3).  The higher levels of rosuvastatin observed in individuals of Asian ancestry have been attributed', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='VOLUME 111 NUMBER 5 | May 2022 | www.cpt-journal.com 1014\nPhenotype Implications Dosing recommendationsClassification of \nrecommendationsaConsiderations\nLovastatin\nSLCO1B1 decreased \nfunction or SLCO1B1 \npossible decreased \nfunctionIncreased lovastatin acid \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe an alternative statin depending on the \ndesired potency (see Figure\xa01 for recommendations \nfor alternative statins). If lovastatin therapy is \nwarranted, limit dose to ≤20\xa0mg/dayModerate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased lovastatin \nacid exposure as \ncompared with normal \nand decreased function, \nwhich may translate to', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:1. Choose an alternativeDo not select simvastatin, as this is also affected by the SLCO1B1 gene variation. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms, but are not influenced byCYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced significantly by SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.Patient has NO additional significant risk factors for statin-induced myopathy:1. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Turner RM et al. A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clin Pharmacol Ther 2020 Mar 3 [Epub ahead of print].2. Liu JE et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='lovastatin,,,,"SLCO1B1 *2/*5,SLCO1B1 *2/*9,SLCO1B1 *2/*15,SLCO1B1 *2/*23,SLCO1B1 *2/*31,SLCO1B1 *2/*46,SLCO1B1 *2/*47,SLCO1B1 *2/*48,SLCO1B1 *2/*49,SLCO1B1 *3/*5,SLCO1B1 *3/*9,SLCO1B1 *3/*15,SLCO1B1 *3/*23,SLCO1B1 *3/*31,SLCO1B1 *3/*46,SLCO1B1 *3/*47,SLCO1B1 *3/*48,SLCO1B1 *3/*49,SLCO1B1 *4/*5,SLCO1B1 *4/*9,SLCO1B1 *4/*15,SLCO1B1 *4/*23,SLCO1B1 *4/*31,SLCO1B1 *4/*46,SLCO1B1 *4/*47,SLCO1B1 *4/*48,SLCO1B1 *4/*49,SLCO1B1 *5/*6,SLCO1B1 *5/*7,SLCO1B1 *5/*8,SLCO1B1 *5/*10,SLCO1B1 *5/*11,SLCO1B1 *5/*12,SLCO1B1 *5/*13,SLCO1B1 *5/*16,SLCO1B1 *5/*19,SLCO1B1 *5/*24,SLCO1B1 *5/*25,SLCO1B1 *5/*26,SLCO1B1 *5/*27,SLCO1B1 *5/*28,SLCO1B1 *5/*29,SLCO1B1 *5/*30,SLCO1B1 *5/*32,SLCO1B1 *5/*33,SLCO1B1 *5/*34,SLCO1B1 *5/*36,SLCO1B1 *5/*38,SLCO1B1 *5/*39,SLCO1B1 *5/*40,SLCO1B1 *5/*41,SLCO1B1 *5/*42,SLCO1B1 *5/*43,SLCO1B1 *5/*44,SLCO1B1 *5/*45,SLCO1B1 *6/*9,SLCO1B1 *6/*15,SLCO1B1 *6/*23,SLCO1B1 *6/*31,SLCO1B1 *6/*46,SLCO1B1 *6/*47,SLCO1B1 *6/*48,SLCO1B1 *6/*49,SLCO1B1 *7/*9,SLCO1B1 *7/*15,SLCO1B1 *7/*23,SLCO1B1 *7/*31,SLCO1B1 *7/*46,SLCO1B1 *7/*47,SLCO1B1 *7/*48,SLCO1B1 *7/*49,SLCO1B1 *8/*9,SLCO1B1 *8/*15,SLCO1B1 *8/*23,SLCO1B1 *8/*31,SLCO1B1 *8/*46,SLCO1B1 *8/*47,SLCO1B1 *8/*48,SLCO1B1 *8/*49,SLCO1B1 *9/*10,SLCO1B1 *9/*11,SLCO1B1 *9/*12,SLCO1B1 *9/*13,SLCO1B1 *9/*16,SLCO1B1 *9/*19,SLCO1B1 *9/*24,SLCO1B1 *9/*25,SLCO1B1 *9/*26,SLCO1B1 *9/*27,SLCO1B1 *9/*28,SLCO1B1 *9/*29,SLCO1B1 *9/*30,SLCO1B1 *9/*32,SLCO1B1 *9/*33,SLCO1B1 *9/*34,SLCO1B1 *9/*36,SLCO1B1 *9/*38,SLCO1B1 *9/*39,SLCO1B1 *9/*40,SLCO1B1 *9/*41,SLCO1B1 *9/*42,SLCO1B1 *9/*43,SLCO1B1 *9/*44,SLCO1B1 *9/*45,SLCO1B1 *10/*15,SLCO1B1 *10/*23,SLCO1B1 *10/*31,SLCO1B1 *10/*46,SLCO1B1 *10/*47,SLCO1B1 *10/*48,SLCO1B1 *10/*49,SLCO1B1 *11/*15,SLCO1B1 *11/*23,SLCO1B1 *11/*31,SLCO1B1 *11/*46,SLCO1B1 *11/*47,SLCO1B1 *11/*48,SLCO1B1 *11/*49,SLCO1B1 *12/*15,SLCO1B1 *12/*23,SLCO1B1 *12/*31,SLCO1B1 *12/*46,SLCO1B1 *12/*47,SLCO1B1 *12/*48,SLCO1B1 *12/*49,SLCO1B1 *13/*15,SLCO1B1 *13/*23,SLCO1B1 *13/*31,SLCO1B1 *13/*46,SLCO1B1 *13/*47,SLCO1B1 *13/*48,SLCO1B1 *13/*49,SLCO1B1 *15/*16,SLCO1B1 *15/*19,SLCO1B1 *15/*24,SLCO1B1 *15/*25,SLCO1B1 *15/*26,SLCO1B1 *15/*27,SLCO1B1 *15/*28,SLCO1B1 *15/*29,SLCO1B1 *15/*30,SLCO1B1 *15/*32,SLCO1B1 *15/*33,SLCO1B1 *15/*34,SLCO1B1 *15/*36,SLCO1B1 *15/*38,SLCO1B1 *15/*39,SLCO1B1 *15/*40,SLCO1B1 *15/*41,SLCO1B1 *15/*42,SLCO1B1 *15/*43,SLCO1B1 *15/*44,SLCO1B1 *15/*45,SLCO1B1 *16/*23,SLCO1B1 *16/*31,SLCO1B1 *16/*46,SLCO1B1 *16/*47,SLCO1B1 *16/*48,SLCO1B1 *16/*49,SLCO1B1 *19/*23,SLCO1B1 *19/*31,SLCO1B1 *19/*46,SLCO1B1 *19/*47,SLCO1B1 *19/*48,SLCO1B1 *19/*49,SLCO1B1 *23/*24,SLCO1B1 *23/*25,SLCO1B1 *23/*26,SLCO1B1 *23/*27,SLCO1B1 *23/*28,SLCO1B1 *23/*29,SLCO1B1 *23/*30,SLCO1B1 *23/*32,SLCO1B1 *23/*33,SLCO1B1 *23/*34,SLCO1B1 *23/*36,SLCO1B1 *23/*38,SLCO1B1 *23/*39,SLCO1B1 *23/*40,SLCO1B1 *23/*41,SLCO1B1 *23/*42,SLCO1B1 *23/*43,SLCO1B1 *23/*44,SLCO1B1 *23/*45,SLCO1B1 *24/*31,SLCO1B1 *24/*46,SLCO1B1 *24/*47,SLCO1B1 *24/*48,SLCO1B1 *24/*49,SLCO1B1 *25/*31,SLCO1B1 *25/*46,SLCO1B1 *25/*47,SLCO1B1 *25/*48,SLCO1B1 *25/*49,SLCO1B1 *26/*31,SLCO1B1 *26/*46,SLCO1B1 *26/*47,SLCO1B1 *26/*48,SLCO1B1 *26/*49,SLCO1B1 *27/*31,SLCO1B1 *27/*46,SLCO1B1 *27/*47,SLCO1B1 *27/*48,SLCO1B1 *27/*49,SLCO1B1 *28/*31,SLCO1B1 *28/*46,SLCO1B1 *28/*47,SLCO1B1 *28/*48,SLCO1B1 *28/*49,SLCO1B1 *29/*31,SLCO1B1 *29/*46,SLCO1B1 *29/*47,SLCO1B1 *29/*48,SLCO1B1 *29/*49,SLCO1B1 *30/*31,SLCO1B1 *30/*46,SLCO1B1 *30/*47,SLCO1B1 *30/*48,SLCO1B1 *30/*49,SLCO1B1 *31/*32,SLCO1B1 *31/*33,SLCO1B1 *31/*34,SLCO1B1 *31/*36,SLCO1B1 *31/*38,SLCO1B1 *31/*39,SLCO1B1 *31/*40,SLCO1B1 *31/*41,SLCO1B1 *31/*42,SLCO1B1 *31/*43,SLCO1B1 *31/*44,SLCO1B1 *31/*45,SLCO1B1 *32/*46,SLCO1B1 *32/*47,SLCO1B1 *32/*48,SLCO1B1 *32/*49,SLCO1B1 *33/*46,SLCO1B1 *33/*47,SLCO1B1 *33/*48,SLCO1B1 *33/*49,SLCO1B1 *34/*46,SLCO1B1 *34/*47,SLCO1B1 *34/*48,SLCO1B1 *34/*49,SLCO1B1 *36/*46,SLCO1B1 *36/*47,SLCO1B1 *36/*48,SLCO1B1 *36/*49,SLCO1B1 *38/*46,SLCO1B1 *38/*47,SLCO1B1 *38/*48,SLCO1B1 *38/*49,SLCO1B1 *39/*46,SLCO1B1 *39/*47,SLCO1B1 *39/*48,SLCO1B1 *39/*49,SLCO1B1 *40/*46,SLCO1B1 *40/*47,SLCO1B1 *40/*48,SLCO1B1 *40/*49,SLCO1B1 *41/*46,SLCO1B1 *41/*47,SLCO1B1 *41/*48,SLCO1B1 *41/*49,SLCO1B1 *42/*46,SLCO1B1 *42/*47,SLCO1B1 *42/*48,SLCO1B1 *42/*49,SLCO1B1 *43/*46,SLCO1B1 *43/*47,SLCO1B1 *43/*48,SLCO1B1 *43/*49,SLCO1B1 *44/*46,SLCO1B1 *44/*47,SLCO1B1 *44/*48,SLCO1B1 *44/*49,SLCO1B1 *45/*46,SLCO1B1 *45/*47,SLCO1B1 *45/*48,SLCO1B1 *45/*49",SLCO1B1 Possible Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Clinical SLCO1B1*17 is associated with an increased risk of simvastatin-induced myopathy. Chan, et al. (2019) (139)   Weak Clinical SLCO1B1 rs4149056 C (c.521T>C) polymorphism markedly affects the pharmacokinetics of active simvastatin acid, but has no significant effect on parent simvastatin. Pasanen, et al. (2006) (4) Zhou, et al. (2013) (140) Tsamandouras, et al. (2014) (141) High', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='CYP3A5 protein). While neither variant has been shown to predict myopathy while on atorvastatin, Wilke et al. describe an association for these variants with the severity of muscle damage in a small cohort of 68 patients who reported myalgias while taking  atorvastatin (27). Although significant, the effect size was modest. For patients with myalgias on atorvastatin, the median CK level was 321 units/L in carriers of the CYP3A4*1B allele, vs 246 units/L in non-carriers (adjusted p = 0.059), and the median CK level was 318 units/L in carriers of the CYP3A5*3 allele, vs 246 units/L in non-carriers (adjusted p = 0.010).', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='or pharmacodynamics of other statins are not affected. To date, studies have focused on two alleles, CYP2C9*2 (decreased function) and CYP2C9*3 (no function). Hirvensalo et al. showed that for fluvastatin the AUC was 25% and 75% greater per copy of the CYP2C9*2 and CYP2C9*3 variant allele, respectively. Additionally, CYP2C9*2 and CYP2C9*3 alleles are associated with increased risk of fluvastatin-induced adverse effects, including liver toxicity and SAMS. However, the evidence supporting increased risk of myopathy in carriers of decreased or poor function alleles of CYP2C9 is of moderate quality and mainly based on the pharmacokinetic evidence. Genetic variation in CYP2C9 has not been associated with fluvastatin lipid-lowering response.   CYP3A4 and CYP3A5.  To date, studies have focused on two alleles, CYP3A4*1B (a promoter variant) and CYP3A5*3 (harboring a common intronic variant causing a splice defect which leads to truncated inactive CYP3A5 protein). While neither variant has', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='29 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  TABLE S5.  EVIDENCE LINKING CYP3A4/5 GENOTYPE WITH STATIN PHENOTYPE  Type of experimental model (in vitro, in vivo preclinical, or clinical) Major Findings References  Level of Evidence Clinical CYP3A5*3/*3 genotype (6986A>G) is associated with simvastatin-induced muscle symptoms. Shek, et al. (2017) (134) Liu, et al. (2017) (91)  Weak Clinical  CYP3A5*3/*3 genotype (6986A>G) is more frequent in statin-intolerant cases. Shek, et al. (2018) (162) Weak Clinical CYP3A5*3/*3 genotype (6986A>G) is associated with simvastatin-induced liver symptoms. Shek, et al. (2017) (134) Weak Clinical When simvastatin-intolerant patients were switched to rosuvastatin, serious side effect were not observed and many of them carry CYP3A5*3/*3. Shek, et al. (2018) (162) Weak Clinical  CYP3A4 rs2740574 (G>A) G allele is associated with smaller risk of a dose decrease or switch to another drug during simvastatin and atorvastatin', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='statin-related myopathy risk: a meta-analysis of case-control studies. Medicine (Baltimore) 2015;94:e1268.6. Luzum JA et al. Individual and combined associations of genetic variants in CYP3A4, CYP3A5, and SLCO1B1 with simvastatin and simvastatin acid plasma concentrations. J Cardiovasc Pharmacol 2015;66:80-5.7. Dou Y et al. Meta-analysis of the SLCO1B1 c.521T>C variant reveals slight influence on the lipid-lowering efficacy of statins. Ann Lab Med 2015;35:329-35.8. de Keyser CE et al. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics 2014;24:43-51.9. Carr DF et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the Clinical Practice Research Datalink. Clin Pharmacol Ther 2013;94:695-701.10. Hopewell JC et al. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. Eur', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient has increased fucntion for the SLCO1B1 gene,  do I need to adjust his statin dosage?
retrieved_docs: [Document(page_content='simvastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='simvastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='lovastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='rosuvastatin,,ABCG2 rs2231142 reference (G)/rs2231142 variant (T),ABCG2 Decreased Function,,SLCO1B1 No Result,,Post-test,"This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *14/*14,SLCO1B1 *14/*20,SLCO1B1 *20/*20",SLCO1B1 Increased Function,,No CDS,n/a\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='atorvastatin,,,,"SLCO1B1 *5/*5,SLCO1B1 *5/*9,SLCO1B1 *5/*15,SLCO1B1 *5/*23,SLCO1B1 *5/*31,SLCO1B1 *5/*46,SLCO1B1 *5/*47,SLCO1B1 *5/*48,SLCO1B1 *5/*49,SLCO1B1 *9/*9,SLCO1B1 *9/*15,SLCO1B1 *9/*23,SLCO1B1 *9/*31,SLCO1B1 *9/*46,SLCO1B1 *9/*47,SLCO1B1 *9/*48,SLCO1B1 *9/*49,SLCO1B1 *15/*15,SLCO1B1 *15/*23,SLCO1B1 *15/*31,SLCO1B1 *15/*46,SLCO1B1 *15/*47,SLCO1B1 *15/*48,SLCO1B1 *15/*49,SLCO1B1 *23/*23,SLCO1B1 *23/*31,SLCO1B1 *23/*46,SLCO1B1 *23/*47,SLCO1B1 *23/*48,SLCO1B1 *23/*49,SLCO1B1 *31/*31,SLCO1B1 *31/*46,SLCO1B1 *31/*47,SLCO1B1 *31/*48,SLCO1B1 *31/*49,SLCO1B1 *46/*46,SLCO1B1 *46/*47,SLCO1B1 *46/*48,SLCO1B1 *46/*49,SLCO1B1 *47/*47,SLCO1B1 *47/*48,SLCO1B1 *47/*49,SLCO1B1 *48/*48,SLCO1B1 *48/*49,SLCO1B1 *49/*49",SLCO1B1 Poor Function,,Post-test,"This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'})]

question: My patient is on atorvastatin and seems to be developing atorvastatin induced myopathy. I have ordered a PGx test and results show that she has decreased function in slco1b1, what are CPIC recommendations?
retrieved_docs: [Document(page_content='atorvastatin,,,,,SLCO1B1 No Result,,Pre-test,SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='3 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  TABLE OF CONTENTS CPIC Updates.................................................................................................................................. 4 Literature Review ............................................................................................................................ 4 Available Genetic Test Options ...................................................................................................... 5 Linking genetic variability to variability in drug-related phenotypes ............................................ 6 Levels of evidence .......................................................................................................................... 9 Strength of dosing recommendations ............................................................................................ 10 Other Considerations', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 45  (237) Shin, J., Pauly, D.F., Pacanowski, M.A., Langaee, T., Frye, R.F. & Johnson, J.A. Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. Pharmacotherapy  31, 942-50 (2011).', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='CPIC guidelines for SLCO1B1 and simvastatin-induced myopathy- Supplement v2.0 33  (20) Postmus, I. et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun  5, 5068 (2014). (21) Keskitalo, J.E., Zolk, O., Fromm, M.F., Kurkinen, K.J., Neuvonen, P.J. & Niemi, M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther  86, 197-203 (2009). (22) DeGorter, M.K. et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet  6, 400-8 (2013). (23) Bai, X. et al. Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites. Acta Pharmacol Sin  40, 492-9 (2019). (24) Chu, A.Y. et al. Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein-Related Measures. Circ', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='1 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  Supplemental Material  The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms Authors:  *Rhonda M. Cooper-DeHoff1,2,  *Mikko Niemi3,4,5, Laura B. Ramsey6,7, Jasmine A. Luzum8, E. Katriina Tarkiainen3,4,5, Robert J. Straka9, Li Gong10, Sony Tuteja11, Russell A. Wilke12, Mia Wadelius13, Eric A. Larson12, Dan M. Roden14,15, Teri E. Klein10, Sook Wah Yee16, Ronald M. Krauss17, Richard M. Turner18, Latha Palaniappan19, Andrea Gaedigk20, Kathleen M. Giacomini16, Kelly E. Caudle22, Deepak Voora23  1Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, Florida, USA 2Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA 3Department of', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='pitavastatin,,,,"SLCO1B1 *1/*5,SLCO1B1 *1/*9,SLCO1B1 *1/*15,SLCO1B1 *1/*23,SLCO1B1 *1/*31,SLCO1B1 *1/*46,SLCO1B1 *1/*47,SLCO1B1 *1/*48,SLCO1B1 *1/*49,SLCO1B1 *5/*14,SLCO1B1 *5/*20,SLCO1B1 *5/*37,SLCO1B1 *9/*14,SLCO1B1 *9/*20,SLCO1B1 *9/*37,SLCO1B1 *14/*15,SLCO1B1 *14/*23,SLCO1B1 *14/*31,SLCO1B1 *14/*46,SLCO1B1 *14/*47,SLCO1B1 *14/*48,SLCO1B1 *14/*49,SLCO1B1 *15/*20,SLCO1B1 *15/*37,SLCO1B1 *20/*23,SLCO1B1 *20/*31,SLCO1B1 *20/*46,SLCO1B1 *20/*47,SLCO1B1 *20/*48,SLCO1B1 *20/*49,SLCO1B1 *23/*37,SLCO1B1 *31/*37,SLCO1B1 *37/*46,SLCO1B1 *37/*47,SLCO1B1 *37/*48,SLCO1B1 *37/*49",SLCO1B1 Decreased Function,,Post-test,"This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information."\n', metadata={'link': '', 'source': 'All Statins SLCO1B1 CYP2C9 ABCG2 Phenotypes Diplotypes Pre and Post Test Alerts'}), Document(page_content='Page 14 of 28Accepted Manuscript\n14 \n - a posterori  genotyping: a SLCO1B1  test may be indicated after initiating treatment to \nexplain muscle symptoms in a patient taki ng statins (myalgia and/or muscle weakness with \nor without elevation of creatinine phosphokinase levels).  \n \n \nResults  (drug selection, contraindications,  dosage)  \n \nStatin exposure (especially with simvastatin) and risk of myopathy are always higher in p atients \nwho are carriers of one or more SLCO1B1  alleles associated with OATP1B1  deficiency . This risk \nof myopathy is correlated with administered dose, the degree of the OATP1B1 activity deficit, and \ntreatment combination with OATP1B1 and/or CYP3A4/5 isofo rm inhibitors (e.g. ciclosporin). The \nmain risk factors for statin -related myotoxicity are: genetic ( e.g. SLCO1B1, CYP3A4/5,…), \npathophysiological (kidney failure, history of myopathy, diabetes mellitus, very young or very old', metadata={'link': 'http://dx.doi.org/doi:10.1016/j.therap.2016.09.017', 'source': 'Fabien LamoureuxThomas Duflotthe French Network of Pharmacogenetics (RNPGX), Pharmacogenetics in cardiovascular diseases (2017), http://dx.doi.org/10.1016/j.therap.2016.09.017'}), Document(page_content='function or SLCO1B1 \npossible decreased \nfunctionIncreased atorvastatin \nexposure as compared \nwith normal function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤40\xa0mg as a starting dose and adjust \ndoses of atorvastatin based on disease-  specific \nguidelines. Prescriber should be aware of possible \nincreased risk for myopathy especially for 40-  mg \ndose. If dose >40\xa0mg needed for desired efficacy, \nconsider combination therapy (i.e., atorvastatin plus \nnonstatin guideline-  directed medical therapy)3Moderate The potential for drug–  drug interactions \nand dose limits based on renal and hepatic \nfunction should be evaluated prior to \ninitiating a statin. The effects of drug–  drug \ninteractions may be more pronounced, \nresulting in a higher risk of myopathy\nSLCO1B1 poor function Increased atorvastatin \nexposure as compared \nwith normal and \ndecreased function, \nwhich may translate to \nincreased myopathy riskPrescribe ≤20\xa0mg as a starting dose and adjust', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'}), Document(page_content='Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:1. Choose an alternativeDo not select simvastatin, as this is also affected by the SLCO1B1 gene variation. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms, but are not influenced byCYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced significantly by SLCO1B1 gene variation or CYP3A4 inhibitors.2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.Patient has NO additional significant risk factors for statin-induced myopathy:1. Advise the patient to contact their doctor in the event of muscle symptoms.Literature:1. Turner RM et al. A genome-wide association study of circulating levels of atorvastatin and its major metabolites. Clin Pharmacol Ther 2020 Mar 3 [Epub ahead of print].2. Liu JE et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity', metadata={'link': 'https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2020.pdf', 'source': 'Royal Dutch Pharmacists Association - Pharmacogenetics Working Group Guidelines'}), Document(page_content='24 CPIC guidelines for SLCO1B1 and statin-induced myopathy- Supplement v3.0  Clinical ABCG2 rs2231142 (c.421C>A) is significantly associated with atorvastatin exposure. Keskitalo, et al. (2009) (21) DeGorter, et al. (2013) (22) Birmingham, et al. (2015) (101) Tsamandouras, et al. (2017) (180) Lee, et al. (2019) (106) Weak', metadata={'link': 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072/', 'source': 'Supplemental Material - Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.'})]

question: What are the implications of having a SLCO1B1 increased function phenotype?
retrieved_docs: [Document(page_content='Patients with the SLCO1B1 Diplotype *1/*5 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*9 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *1/*23 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *3/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *6/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *7/*9 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *20/*31 display a SLC01B1 Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *15/*25 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'}), Document(page_content='Patients with the SLCO1B1 Diplotype *2/*31 display a SLC01B1 Possible Decreased Function phenotype. The corresponding EHR notation for this diplotype categorizes it as Abnormal/Priority/High Risk.\n', metadata={'link': '', 'source': 'SLCO1B1 Diplotypes to Phenotypes Mapping'})]

